In regard with evolution, troponin I maintained a decreasing tendency in ICU (x0.78) and in CAR (x0.77). CK requests decreased more in the ED (x0.28) than in the ICU (x0.55) or CAR (x0.42) . No CKMB requests were recorded beyond mid-2016.
Conclusions
The introduction of hsTnI and the implementation of the new AMI protocol in our hospital did not lead to an increase troponin requests, and could help in a better management of other less specific tests, achieving a reduction of 10,804 CK determinations and the total of determinations of CKMB (8243) 
Background-aim
The possibility of determination of ionized magnesium (iMg), the only physiologically active form of Mg, with ionoselective electrode analyzers increased the interest of the clinicians for this "forgotten element". Although the procedure is not fully standardized, the actual results indicate the need for estimating iMg levels in circulation.
Methods
The study involved 91 patients with acute myocardial infarction (AMI). After anaerobic blood collection, the levels of iMg in serum were analyzed promptly using the AVL 988/4 ion selective analyzer. Total magnesium (tMg) levels were determined colorimetrically by xylidyl blue and creatine kinase (CK) activities were determined spectrophotometrically. Venous blood was collected at admission, during the following four days and on the tenth day. The same biochemical parameters were examined in a reference population.
Results
In 36 of patients (60%) decreased concentrations of iMg were found during the first 24 h after the onset of AMI, and in 24 of patients (40%) on the following day. The second group, relative to the first, is characterized by a higher incidence of patients with a CK peak N1800 U/L, a lower incidence of patients with a CK peak below 1000 U/L, a greater proportion of the number of deceased (all), a greater presence of previous AMIs, a greater presence of smokers and a higher application of beta blockers. Normalization of iMg values of these patients was much slower during hospitalization. However, tMg concentrations in both groups were not reduced a single day.
Conclusions
The level of iMg does not decrease significantly immediately after AMI, but after N12 h. The presence of patients with extensive AMI was greater in the group of patients with lower iMg values on the second day of the determination. Because of the more serious health condition and more severe unpleasant symptoms, these patients earlier requested medical attention. 
Background-aim
The diagnosis of acute coronary syndrome (ACS) is based on the combination of clinical characteristics and specific findings in the electrocardiogram (ECG) together with elevated and rising concentrations of cardiac troponins. Previously, creatine kinase-MB (CK-MB) was also used in the diagnosis of ACS. However, following the introduction of highly sensitive methods for troponin T (TnT-hs), CK-MB is only considered relevant 1) to determine whether an increase in TnT in case of an increased creatinine might be due to myocardial damage or kidney failure or 2) in case of suspected early re-infarction, when TnT has still not returned to normal values. We investigated the use of CK-MB relative to TnT in 6 hospitals receiving patients with acute cardiac diseases in the Region of Southern Denmark.
Methods
Numbers of TnT and CK-MB tests performed in the hospitals in the region in 2018 were extracted from the joint IT-production system of the biochemical laboratories. Ratios between CK-MB and TnT for the 6 hospitals were calculated. The optimal ratio was estimated using data from one of the hospitals, and on the basis of this estimate, the total potential savings of CK-MB tests in the region was calculated.
Results
The ratios, with the absolute numbers of CK-MB/TnT in brackets, were: Hospital 1: 2.5% (162/6499); Hospital 2: 4.5% (82/1831); Hospital 3: 59.6% (5346/8967); Hospital 4: 39.2% (1935/4935); Hospital 5: 14.2% (1202/8436) and Hospital 6: 26.0% (4152/15,971) . Based on data from Hospital 5, the optimal ratio of CK-MB/TnT was estimated to be in the range of 6% -10%. Using these ratios in the entire region, it can be calculated that approximately 7000-9400 CKMB tests might be saved per year.
Conclusions
In the Region of Southern Denmark, approximately 2/3 of the requested CK-MB analyses are estimated to be inappropriate with large variations between the hospitals in the region. 
Background-aim
To assess the contribution of biochemical parameters to the diagnosis of lesions of target organs in patients with arterial hypertension and abdominal obesity.
Methods
153 patients (mean age 57.2 ± 7.6) were included in the study and randomized into 3 groups. The Gr.1 included 42 healthy women, Gr.2-59 subjects with AH degree I-III without metabolic disorders and Gr.3-52 subjects with AH and AO. The body mass (BM), body mass index (BTI), waist volum (WV) were measured.The parameters of sphygmography by VASERA VS-1000 «FUCUDA»; 24-h blood pressure monitoring using AВМP-04 MEDITEX device; biochemical parameters (total cholesterol, low-density lipoprotein cholesterol (LDL-chol), APO-a, APO-B, high-density lipoprotein cholesterol (HDL-chol), triglycerides (Tg); inflammatory markers (homocysteine, hs-CRP, uric acid), endothelial dysfunction (endothelin-1, nitritis), interleukins (IL 6, 8, 10) , sex hormones; cystatin, microalbuminuria, glomerular filtration rate (MDRD) were estimated.
Results
In Gr.2 and 3 there were registered: significant increase in sphygmography indexis (pulse wave velocity PWV, cardio-ankle vascular index CAVI) and decrease ancle-brachial index ABI; significant increase in mean 24-h and mean daytime systolic BP (SBP), in day and nigth time SBP and DBP variability. In biochemical parametrs significant increase in total cholesterol, LDL-chol., triglycerides level, and in inflammatory markers -homocysteine, hs-CRP ang TNF-alpha levels; decrease HDL-chol. Compared to the patients in Gr.1. Besides in Gr.2 there were registered correlation between lipid and inflammatory markers with parameters of sphygmography (positive associations PWV and CAVI with LDL-chol., ApоВ, homocysteine, and negative connections with nitritis and sex hormones). In Gr.3 elevated levels of leptin, uric acid, cystotin, homocysteine, hs-CRP, interleukin 1b were also detected. The interrelations of BMI with hsCRP(p = 0,0001) and ApoA (p = −0,034), leptin (p = 0,033); daytime SAD and DAD with total cholesterol (p = 0,033), 05) and nitrites (p = −0,016); daytime SAD variability with total cholesterol, endothelin-1 (p b 0,05); PWV with the level of Tg (p = 0,006), hsCRP (p = 0,009), homocysteine (p = 0,287), adrenaline (p = 0,05); MDRD with microalbuminuria (p = 0,004) and uric acid (p = 0,046), microalbuminuria with glucose (p = 0,006) and homocysteine (p = 0,02) were revealed.
Conclusions
The level of biochemical markers reliably reflects the degree of damage to target organs in patients with arterial hypertension and adominal obesity. 
Background-aim
Acute myocardial infarction (AMI) is normally diagnosed biochemically using cardiac troponins, either troponin I (TnI) or troponin T (TnT). However, especially when using TnT, this marker should be supplemented by CK-MB in two scenarios; 1) suspicion of AMI in a patient with kidney dysfunction and 2) suspicion of early re-infarction. Here, we investigated whether CK-MB is requested appropriately, based on biochemical data.
Methods
At our department, CK-MB can be requested in two ways; 1) by way of an algorithm that requests CK-MB if TnT N 14 μg/L and creatinine (Crea) N 150 μmol/L or 2) by phoning the laboratory and making a request in case of re-infarction. In order to determine the current use of CK-MB, all TnT's requested in 2017 and 2018, including those with corresponding Crea and CK-MB was extracted from the laboratory information system.
Biochemically, we considered CK-MB appropriate if 1) Crea N150 μmol/L and TnT N 14 μg/L or 2) Crea b150 μmol/L and TnT N 14 μg/L, and inappropriate if 1) Crea N150 μmol/L and TnT b 14 μg/L or 2) Crea b150 μmol/L and TnT b 14 μg/L.
Results
Based on the above mentioned criteria, we found that only 67 (3.0%) of 2242 requested CK-MB's were inappropriate. Of the 67 patients with inappropriately requested CK-MB, there were 32 women and 35 men. Of those, only two women had marginally raised CK-MB.
Conclusions
In our hospital, most of the performed CK-MB's are requested appropriately according to the biochemical criteria. However, a large proportion of the CK-MB's are requested by the algorithm. An improvement to the algorithm, where it takes into account previously performed CK-MB's in a specified time period may help decrease the number of CK-MB performed, as serially measured CK-MB's are not needed for diagnosis. doi:10.1016/j.cca.2019.03.358
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Algorithm development for high sensitivity cardiac troponin I measurement in a tertiary hospital and application results in an emergency setting C. Queiroz, C. Pereira, Â. Maresch, L. Araújo, G. Marques, C. Chaves, F. Rodrigues Centro Hospitalar e Universitário de Coimbra, Clinical Pathology, Coimbra, Portugal
Background-aim
Chest pain is one of the most common symptoms in patients attending the emergency department (ED), making its adequate evaluation of utmost importance. The diagnosis of non-ST segment MI depends on the early detection of cardiac troponin (cTn) and new assays of high sensitivity cTn (hs-cTn) have been recently introduced, with the potential to alter patient management.
Methods
Review of the development and application of a diagnostic algorithm for the use of hs-cTn in patients with chest pain. This algorithm was developed by the clinical pathology department in collaboration with the cardiology and ED. Results of hs-cTn in the ED, between April-June 2018 were evaluated according to the algorithm.
Results
For optimal use of the hs-cTn assay an algorithm for rule-in and rule-out of MI was developed. Dynamic changes in hs-cTn serial testing as well as cut-off values according to gender were taken into account. The algorithm includes a rule-out value of b5 ng/mL if chest pain N3 h and rule-in if hs-cTn is 10× higher than the 99th centile. For values N99th centile, and b 99th centile but with chest pain b6 h, testing at presentation and at 3 h is recommended, with a change of N50% at 3 h suggestive of MI. For values b99th centile and chest pain N6 h other causes need to be investigated.
A total of 4739 assays were performed in the ED -4118 first assessments and 621 serial tests. Out of the first assessments, 51.4% of patients fell into the rule-out and 5,1% into the rule-in categories. Although 1791 fell into the categories where serial testing was recommended only 34.7% (621) patients had serial tests with 34,3% out of those falling into a profile suggestive of MI.
Conclusions
The use of hs-cTn assays in clinical practice has many advantages as long as an algorithm is developed. While earlier rule-out is seen as one of the major advantages of hs-cTn assays, a rule-in capable of accurate identification of patients with MI is also important as both approaches can potentially reduce costs and improve outcomes. It's also critical to evaluate dynamic changes with serial testing and not interpret hs-cTn as a binary assay. Our preliminary results show that the algorithm has a high percentage of rule-outs and that from the patients with recommended serial tests only a small percentage are re-tested in the ED setting. 
Background-aim
Apoptotic cell death may play a critical role in a variety of cardiovascular diseases, especially in those developing on the basis of atherosclerosis. The goal of this study was to compare the activity of caspase-3 and values of Bcl-2 protein in sera in patients with various forms of ischemic heart disease, and to correlate these markers with inflammatory and lipid parameters.
Methods
We studied 30 patients with chronic stable angina pectoris (SAP), 27 with unstable angina pectoris (USAP), 39 with acute ST-elevation myocardial infarction (STEMI) and 27 age-matched healthy volunteers (Control group). Caspase-3 activity was determined by a colorimetric commercially available method while serum Bcl-2 concentrations were determined using commercially available immunoassays (ELISA).
Results
Caspase-3 was significantly higher only in the USAP group (0.122 ± 0.062 ⎧mol/mg protein, p b .05) in comparison with the control group (0.092 ± 0.022 ⎧mol/mg protein). Concentrations of Bcl-2 were significantly higher in patients with SAP (0.310 ± 0.075 ng/mL) and USAP (0.329 ± 0.102 ng/mL) compared to healthy (0.250 ± 0.069 ng/mL, p b .01) and the STEMI (0.266 ± 0.041 ng/mL, p b .01) groups. ROC curve analysis showed that Bcl-2 had the best characteristics in patients with SAP and USAP and represents the best indicator of atherosclerotic plaque activity. However, Bcl-2 could not be a marker of patients' stratification because there was no significant difference between areas of Bcl-2 curves of these two patient groups. These results suggest that simultaneous determination of caspase-3 activity and Bcl-2 can indicate plaque evolution from stable to unstable one.
Conclusions
The studied markers of apoptosis present valuable parameters in evaluation of atherosclerotic plaque acivity and a new targets for drug therapy. Background-aim NT-proBNP is the amino-terminal fragment of the brain natriuretic propeptide, produced mainly by the left ventricle. Its secretion is stimulated by the elongation of the myocardial fibers, by the ischemia and hypoxia of the cardiomyocytes. Any cause of volume overload, mainly heart failure (HF), will produce an increase in the production of this peptide. In the literature consulted there is no consensus on the NT-proBNP cut-off point in pleural fluid for the diagnosis of HF.
The objective of this study was to determine the optimal cut-off point in NT-proBNP levels in pleural fluids for the diagnosis of pleural effusions secondary to HF.
Methods
Descriptive and retrospective study, carried out during one year (August 2017 -July 2018 , in which all the pleural fluids that had NTproBNP results were analyzed. NT-proBNP levels were measured by electrochemiluminescence immunoassay on the COBAS 8000 analyzer. The etiology of pleural effusions was established by reviewing patients' medical records. The ROC curve made by the MedCalc program were used to analyze the diagnostic efficiency and the cutoff point.
Results
The pleural fluids of the 170 patients studied were classified into 4 groups according to the etiology of the pleural effusion: cardiac, neoplastic, infectious and others. The NT-proBNP mean in HF was 11,233 pg/mL, while in the cases of stage IV neoplasia was 5124 pg/ mL.
The analysis of the ROC curve determined a value of NT-proBNP of 1706 pg/mL; the sensitivity was 97.5% and the specificity was 86.7%.
Conclusions
The data obtained in the ROC curve indicate that values of NTproBNP higher than 1706 pg/mL allow to diagnose HF with high precision, except in pleural effusions secondary to stage IV neoplasms because tumor cells can produce large concentrations of cardiotoxic substances and vasoactive peptides like the natriuretic peptides.
Pleural fluids obtained in patients with stage IV neoplasms would be misclassified as pleural effusions secondary to HF analyzing only the level of NT-proBNP. Because of this, the request for this test is not justified in cases of advanced neoplasms.
NT-proBNP values should be used as a complement to cardiac images in the diagnosis of HF and should be interpreted taking into account the patient's history, clinical analysis and the results of other tests. 
Background-aim
Anemia is a frequent cause of morbidity in heart failure (HF) and is associated with a poor outcome of the disease. Many factors are implicated in anemia of HF, such as iron deficiency, lack of vitamin B12 and folate. Anemia has been shown to be an independent risk factor for HF and significantly affects the prognosis of the disease. NT-proBNP is a biomarker of HF.
The aim of this retrospective study was to evaluate the relationship between proBNP serum levels and biochemical markers of anemia in patients with advanced HF for the amelioration of the treatment of these patients.
Methods
This study included 40 patients with HF (20 males and 20 females) aged 60.38 ± 15.1 years, recruited from Cardiology Clinic of our Hospital and 40 age-and sex-matched healthy controls. NT-proBNP, B12 and ferritin were measured using electrochemiluminescence, Fe photometrically and TIBC was measured by colorimetric method. All determinations were performed on automated analyzers (Modular E170, Modular P800 and Cobas Integra 400 plus, Roche Diagnostics, respectively). Level of statistical significance was p b .05.
Results
We found that NT-proBNP levels were significantly higher in patients compared to controls (p b .001), while serum B12 levels and Fe levels were significantly lower (p b .001). Positive, but not significant, correlation was found between serum NT-proBNP and B12 levels (r = 0.088, p = .626) and a significant negative correlation was found between serum NT-proBNP and Fe levels (r = −0.352, p = .03) in the study group. In the control group there was no significant correlation between the parameters under study.
Conclusions
In the present study, patients with HF had significantly reduced serum levels of B12 and Fe values. It is considered that the early detection and correction of anemia might improve the prognosis of HF. 
Background-aim
Experimental studies have shown that chemokines are involved in the pathophysiology of the coronary artery disease. They recruit leukocytes into the ongoing inflammatory process within the atherosclerotic plaque.
The aim of the study was to assess the diagnostic utility of the chemokine RANTES/CCL5 concentration as an indicator of the atherosclerotic lesions in ischemic heart disease.
Methods
The study was conducted in 84 patients with acute coronary syndrome (ACS): STEMI and NSTEMI myocardial infarction, 33 patients with stable coronary artery disease (SA), and in 21 healthy subjects. The concentration of RANTES was determined in platelet poor plasma by ELISA method (R&D Systems).
Results
In ACS patients RANTES concentration was almost 3-fold higher (4935 pg/ml) than in healthy subjects (1725 pg/ml) (p b .001). RANTES concentration was higher in NSTEMI patients (5412 pg/ml) than in STEMI patients (3819 pg/ml), but it was not significant. In SA patients RANTES concentration was over 3-fold higher (6042 pg/ml) compared to the control group (p b .001). RANTES concentration was slightly higher in SA than in ACS patients, although it was not significant. In ACS patients RANTES concentration was increasing with the severity of atherosclerotic lesions; the highest value was achieved in patients with ε3 affected coronary vessels (6041 pg/ml) vs. 2-vascular disease (4551 pg/ml) and 1-vascular disease (4006 pg/ ml). On contrary, in SA patients the highest RANTES concentration occurred in patients with 1-vessel disease (6890 pg/ml) and decreased with the number of affected coronary vessels: in 2-vessel disease was 5905 pg/ml and in ε3-vessel disease 5330 pg/ml, however these differences were not significant. RANTES was characterized by good diagnostic power in differentiating patients with ACS from healthy subjects (AUC = 0.825) and excellent diagnostic power in differentiating patients with SA from healthy subjects (AUC = 0.961).
Conclusions
Our results indicate that RANTES may be a useful indicator of the atherosclerotic process and the accompanying inflammatory process in patients with cardiovascular disease, both with ACS and SA, as demonstrated by its high diagnostic power. Assessment of RANTES concentration may be helpful in determining the presence of atherosclerotic lesion, but not in its severity. 
Background-aim
Background: Chest pain is one of the most frequent reasons for emergency ambulance visits. Acute myocardial infarction is the definitive diagnosis in a minority of these patients. Early diagnosis is a significant benefit for these patients. The introduction of high sensitive methods of determining cardiac troponin allows rapid diagnosis and decision on further treatment in most patients. A onehour protocol (0/1 h) is recommended by a professional society if the method used for this test is validated.
Methods
Methods: Part 1) Comparison of methods for determination of troponin I TNI (Siemens Healthineers Vista) with high sensitivity troponin I TNIH (Siemens Healthineers ADVIA Centaur) in patients with chest pain, myocardial infarction, pulmonary embolism and heart failure. Part 2) Prospective study of patients investigated for chest pain using 0/1 h validated protocol TNIH.
Results
Results:1) TNI and TNIH closely correlated in groups of patients with various cardiovascular diseases (R = 0.092, p b .005. 2) In the period from May 1 to June 31, 2018, 135 patients were examined by this 0/1 h protocol. 64 people were included in the rule-out group, 12 in the rule-in group, and 59 in the observation group. Non-STelevation myocardial infarction (STEMI) was the final diagnosis in 8 patients (5.9%), all of whom were included in the rule-in group. Test sensitivity was 100% in our set, specificity 97%, negative predictive value 100%. Patients enrolled in the observation group were older than those in the group rule-out (70.0 ± 14.1 vs. 54.3 ± 14.9, p b .001). They also have often coronary heart disease (44% vs. 14%, p b .001), arterial hypertension (72.9% vs. 35.9%, p b .001) and hyperlipidemia (62.7% vs. 39.1%, p b .05). Patients in the rule-out group were less frequently hospitalized than in the other groups (15.6% vs. 47.5%, p b .001).
Conclusions
Conclusion: A close correlation between the determination of troponin and the high sensitivity troponin (Siemens) was found. The 0/1 h protocol is an effective tool in the care of patients with chest pain. It allows the safe elimination of myocardial infarction in more than half of the cases. Patients included in the observation group are more at risk of various diseases. Our results emphasize that inclusion in the protocol groups does not equal the final diagnosis. 
Background-aim
Infective endocarditis (IE) is still a life-threatening disease with rapid development of heart failure and a high risk of fatal complications. Inflammatory and cardiac tissue damage biomarkers can help in early risk-stratification and can guide decisions on treatment-strategy. The aim of this study was to analyze the prognostic values of: procalcitonin (PCT), C-reactive protein (CRP), cardiac Troponin I (TnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at admission and their role in predicting clinical outcomes.
Methods
Blood samples were taken from 71 (24 women and 47 men) IE patients (age range 22-88) and were analyzed upon admission. The serum TnI and PCT levels was measured by ELISA (Vektor-Best, Russia), CRP and NT-proBNP levels-by chemiluminescent enzyme immunoassay, Immulite 2000 XP ((Siemens Healthcare Diagnostics Inc). During the 1-month observation period, 15 of the patients died within two weeks following admission. Receiver-operating-characteristic curves were generated to identify a reliable cut-off for PCT, CRP, NT-proBNP and TnI in predicting clinical deterioration or death.
Results
The best cut-off value for predicting negative patient outcomes were assessed by a receiving-operator characteristic (ROC) curve analysis: TnI (p = 0,03; area under the ROC [AUROC] = 0,665; optimum cut-off value at 0,1 ng/ml, Se%-67,9, Sp%70,3; CRP (p = 0,04; area under the ROC [AUROC] = 0,667; optimum cut-off value at 93 mg/l, 8; PCT (p = 0, 005 ; area under the ROC [AUROC] = 0,72; optimum cut-off value at 1,1 ng/ml, Se%-72,3 Sp%-64,6; NT-proBNP (p = 0,03; area under the ROC [AUROC] = 0,758; optimum cut-off value at 410 pg/ml, 3. We determined that admissions levels of: CRP ε93 mg/l (relative risk (RR) = 4,2; 95% confidence interval [CI]: 1,6-13,7), TnI ε0,1 ng/ ml (RR = 2,7; 95% confidence interval [CI]: 1,2-6,4), PCTε1,1 ng/ml (RR = 2,7; 95% confidence interval [CI]: 1,3-7,0), NT-proBNPε410 pg/ ml (RR = 2,8; 95% confidence interval [CI]: 1,4-25,2), were an independent predictors of complications or mortality within a 2-week window in IE patients.
Conclusions
The study shows that Procalcitonin (PCT,) C-reactive protein (CRP,) Cardiac Troponin I (TnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in admission may be used as a predictor of adverse outcomes in IE patients, and a useful marker for death risk stratification. 
Background-aim
High sensitivity troponin (Tn) is characterized by total imprecision [coefficient variation (CV)] at the 99th percentile δ10% and measurable concentration below the 99th percentile should be attainable at a concentration above the assay's limit of detection for at least 50% of healthy individuals. This technology will allow to reduce the delay in diagnosis, shorten the stay in the emergency room and reduce costs.
The aim of this study was to compare quantitative differences between high sensitive (TNIH) and ultrasensitive (TNIUltra) TnI in ADVIA Centaur XP (Siemens®) for considered its implementation in our hospital.
Methods
A total of 168 heparinized samples were measured in parallel. Passing-Bablok regression and Bland-Altman statistical analyses were performed to evaluate the correlation and the differences by MedCalc®12.5.
The precision analysis for TNIH was carried out by measuring a reference control material. A total of 10 consecutive measurements were made for the determination of intraserial precision and 9 isolated measurements on consecutive days for the interserial precision.
The 99th percentile and linearity for TNIH and TNIUltra assays were 4.7 pg/mL (2.5-2500 pg/mL) and 0.04 ng/mL (0.006-50 ng/ mL), respectively.
Results
Intraserial precision CV of TNIH was 3.22% for low levels (mean: 6.1 pg/mL) and 1.35% for high levels (mean: 810.8 pg/mL) and interserial precision CV was 2.79% for low levels (mean: 6.2 pg/mL) and 2.07% for high levels (mean: 822.7 pg/mL).
In the comparative study, Bland-Altman test showed proportional differences for higher values and correlation analysis by PassingBablok showed that methods were not interchangeable (Y = -0.0169 + 1.498×; IC95% slope: 1.46-1.54, IC95% intercept:-0.023--0.010).
We obtained measurable concentrations for TNIH in 70% of the samples that were undetectable for TNIUltra.
Conclusions
Even though methods are not interchangeable, both assays offer results over 99th percentile for patients with elevated concentrations of TnI. The improvement of the accuracy and the fact that screening is faster, make TNIH an interesting implementation option for an emergency laboratory. This choice would decrease the number of incomes and the associated costs.
On the other hand, because of the shorter linearity, perhaps more dilutions will be needed for TNIH assay. 
Background-aim
Calcific aortic valve disease (CAVD) is a progressive condition involving calcification and fibrosis of the aortic valve leaflets. Calcified aortic stenosis is common among older people and is one of the most common causes of heart failure. Evidence on the association of vitamin D and parathyroid hormone (PTH) with cardiovascular risk factors in the elderly is limited. We therefore assessed the relationships of serum 25-hydroxyvitamin D (25-OHD) and PTH levels with calcific aortic valve disease.
Methods
Sixty one patients who referred to our cardiology clinic and who had CAVD diagnosed by transthoracic echocardiography and 30 control subjects were included in this study. Serum levels of calcium and alkaline phosphatase (ALP) were determined using standard methods. Serum 25-OHD was measured using a chemiluminescence immunoassay on an Advia Centaur XP analyzer (Siemens Healthineers, Erlangen, Germany). Serum PTH was measured by a chemical immunoassay method with an Immulite Analyzer (Siemens, Llanberis, UK).
Results
The mean age of the subjects was 67 ± 11 years. The mean age of both groups was similar. 25-OHD and PTH levels were 11.0 ± 7.2 ng/ml and 66.4 ± 44.8 pg/ml in the patient group and 18.2 ± 8.2 ng/ml and 48.2 ± 16.3 pg/ml in the control group, respectively. There was statistically significant difference between the patient and control group for 25-OHD and PTH (p = .001). We found that 25-OHD and PTH levels were negatively correlated (r = −0.269 p = .01).
Conclusions
With regard to cardiovascular disease, vitamin D deficiency has been associated with activation of the pro-inflammatory mechanism, promoting atherogenesis. However, it is still unclear whether the serum 25-OHD level can be used as a biomarker for future cardiovascular disease. Results suggest a possible link between serum 25-OHD and the risk for CAVD, but future studies with longer follow-up are needed to further test this association. 
Background-aim
Search for biomarkers of subclinical thrombosis in elderly patients with atrial fibrillation (AF) is of high importance since these patients demonstrate high risk of thrombotic complications of AF. Different strategies are used to minimize the thrombotic risks in AF patients, including the antiplatelet agents and anticoagulants. Ddimer is a known marker of vascular aging and thrombotic risks, but no data exist on its diagnostic value for different antithrombotic strategies in elderly AF patients. The aim of the study was to assess the role of D-dimer plasma level as a marker of thrombosis in aged patients with AF having no signs of active thrombosis, depending on used treatment strategy and quantitative thrombotic and haemorrhagic risk of AF.
Methods
Study design: Prospective evaluation of 52 elderly in-hospital patients with AF (mean age 76.0 ± 8.3 years, 64% females) medicated with either anticoagulant (n = 33) or antiplatelet monotherapy (n = 19). All the patients had no clinical signs of ongoing thrombotic processes. Plasma D-dimer levels were assessed via microlatex agglutination (Instrumentation Laboratory, Bedford, USA) with a cutoff value 230 ⎧g/l DDU for elderly patients. Thrombotic and haemorrhagic risks were assessed by using the frequently used clinical score, including CHADS2, CHA2DS2-VASc, HAS-BLED, ATRIA and HEMORR2HAGES scores. Data on in-hospital mortality were collected for all the patients.
Results
D-dimer plasma levels, despite comparable among 2 groups, correlate with thromboembolism and haemorrhage risk scores in group on antiplatelet agents (CHADS2: r = 0.65, p b .01; CHA2DS2-VASc: r = 0.72, p = .001: HAS-BLED: r = 0.59, p b .05; HEMOR-R2HAGES: r = 0.58 p b .05) but not anticoagulants. High D-dimer level was associated with in-hospital mortality (916.0 ± 1184.0 ⎧g/l DDU vs. 175.5 ± 169.8 ⎧g/l DDU, p b .001) and rhythm of AF at the moment of blood sample collection (270.2 ⎧g/l DDU vs. 128,2 ⎧g/l DDU, p = 0,045).
Conclusions
An accuracy of risk prognosis of fatal complications of AF for elderly patients treated with antiplatelet agents may be increased by using the laboratory markers of thrombus formation such as D-dimer and by using the obtained results to guide an antithrombotic therapy (e.g. to intensify therapy if no D-dimer decrease is reached). 
Background-aim
Atrial fibrillation (AF) is the most common arrhythmia with adverse clinical outcomes. Being in close contact with the heart, the pericardial fluid (PF) mirrors its pathophysiological status. Thus, the characterization of PF proteome may help find novel therapeutic targets and unveil new surrogate markers. Ultimately, these may help establish patient subgroups with increased risk of adverse outcomes.
Methods 70 consecutive patients with severe aortic stenosis (AS) submitted to aortic valve replacement surgery were selected and their PF and clinical baseline data collected. 13 samples were selected blindly for proteome characterization following a shotgun (GeLC-MS/MS) and a label-free quantification (LFQ) approaches. A principal component analysis was used for outlier detection. According to previous AF history, a Partial Least Squares Discriminant Analysis (PLS-DA) was conducted and the top 15 variables important in projection (VIP) were identified. To inquire potential biomarkers, ROC curves were designed using LFQ data.
Results
Median age was 68 years for the sinus rhythm (SR) group (N = 5) and 74 years for the AF group (N = 8) and female gender represented 60% of SR and 50% of AF patients. Arterial hypertension was present on 60% and 88% of patients in each group, respectively. Proteome analysis uncovered 9 proteins up-(e.g. annexin A1) and down-regulated (e.g. properdin) ε2-fold. Annexin A1, annexin A2 and vimentin were among the top 15 most important variables for group discrimination in PLS-DA. Protein-protein interaction and gene ontology enrichment analysis (STRING v10.5) presented functional interaction among the identified proteins which are all part of focal adhesion sites. Therefore, annexin A1, A2 and vimentin were tested as biomarkers using ROC curves. An AUC of 1 (95% CI: 0,812-1) for annexin A1, 0.906(0.656-1) for annexin A2 and 0,844(0.531-1) for vimentin were obtained. Thus, the identified proteins are potentially relevant AF biomarkers.
Conclusions
Focal adhesion molecules such as annexin A1, annexin A2 and vimentin emerge as novel surrogate biomarkers of AF in AS. Their ability to predict adverse outcomes in a large cohort is currently under validation. 
Background-aim
Aerobic exercise is prescribed to patients with coronary artery disease (CAD); however, its uncontrolled practice could promote cardiac damages. Detecting such damages usually requires expensive exercise + image tests not always representative of the usual exercise practice. Biomarkers as high-sensitive cardiac troponins (hscTn) could be a practical alternative to image tests.
To detect if myocardial damage exists in CAD patients after practicing long-duration, aerobic exercise.
Methods
Ten CAD patients and 13 controls (same age and gender) consented to participate in the study. CAD patients were evaluated by a cardiologist previous to authorize their participation. All participants ran/brisk walked during 1 h around the Hospital facilities. Blood samples were obtained immediately before and after the exercise. Myocardial damage was considered to exist when concentrations of hs-cTnI, measured with a method based on singlemolecule counting technology (Clarity hs-cTnI, Singulex Inc.), exceeded the 99th reference percentile of the assay (9.0 ng/L for males).
Results
Before exercise: Mean hs-cTnI was 2.66 ng/L in controls and 3.87 ng/L in CAD patients; only 1 CAD patient -who walked 30 Km the day before-showed an elevated value (16.1 ng/L). Exercise: Controls ran 8.8Km (5.9-10.9Km) and patients 7.5Km (4.2-9.2Km).
After exercise: mean hs-cTnI increased to 4.12 ng/L (51%) in controls and to 5.68 ng/L (45%) in CAD patients. Four subjects exhibited hs-cTnI values N9.0 ng/L: one control (9.3 ng/L) and 3 CAD patients -one was the patient with increased values pre-exercise (22.6 ng/L); the two others showed marginally elevated hs-cTnI (10.8 and 9.6 ng/L) and were the patients that ran faster. hs-cTnI concentrations did not significantly differ between CAD patients and controls either pre and post-exercise, while post-exercise concentrations were strongly associated to pre-exercise ones (r = 0.951).
Conclusions
Hs-cTnI similarly increased in controls and CAD patients after exercise; the major determinant of post-exercise hs-cTnI concentrations being the pre-exercise ones. Except in one CAD patient, heavily exercised the previous day, the hs-cTnI increases existing in few CAD cases were small and suggested the safety of long-duration exercise. 
Background-aim
Obstructive sleep apnea (OSA) which is characterized by repetitive episodes of partial or complete obstruction of the upper part of respiratory system leads to state of hypoxia. Hypoxia stimulates xanthine synthesis through adenosine triphosphate degradation, which further increases uric acid synthesis. There are still controversial data on association of hyperuricemia with the presence and severity of OSA and with increased cardiovascular risk.
The aim of this study was to determine whether the uric acid serum levels could be associated with OSA severity and hypertension.
Methods
The study enrolled 167 patients including 29 patients with mild OSA (apnea/hypopnea index -AHI between 5 and 14.9), 32 patients with average OSA (AHI between 15 and 29.9) and 64 patients with severe OSA (AHI higher than 30) and a control group of 42 patients (AHI b4.9). Basic biochemistry and clinical markers were determined in serum of all participants.
Results
There were significant differences in uric acid concentration between tested groups (p b .001). Uric acid levels were highest in group of patients with severe OSA. Uric acid correlated significantly positively with body mass index, C-reactive protein (CRP) and highly negatively with high-density lipoprotein cholesterol (HDL-c). Also, strong positive correlations were determined between serum uric acid and systolic blood pressure during night (〉 = 0.375, p = .001) and AHI (〉 = 0.464, p b .001). Logistic ordinal regression analysis revealed that serum uric acid levels were associated with the severity of OSA (OR = 1.010, 95%CI 1.006-1.013, p = .001) and as well as with the presence of hypertension (OR = 1.006, 95%1.001-1.011, p = .011). Multivariate regression analysis demonstrated independent associations of uric acid and AHI (OR = 1.008, 95%CI 1.004-1.012, p = .012) and, as well as, uric acid and hypertension (OR = 1.007, 95%CI 1.001-1.014, p = .030) after adjustment for other biochemical markers as potential confounders.
Conclusions
Uric acid levels could be a useful marker for OSA severity determination and also indicator of hypertension presence in these patients. 
Background-aim
There is increasing need for faster rule-in or rule-out of acute myocardial infarction (AMI) in patients. High-sensitivity troponin I (hsTnI) are playing an indispensable role in this area by measuring cTnI concentrations in serial samples more accurately and precisely. This study aimed to evaluate the analytical performances of the novel hsTnI and other cardiac markers on Atellica Immunoassay (IM) Analyzer (Siemens, USA).
Methods
We evaluated the analytical performances of cardiac markers including hsTnI, myoglobin, CK-MB, BNP and NT-proBNP on Atellica IM Analyzer. The specimens for the assays were heparinized plasma except BNP, EDTA plasma. Precision, linearity, method comparison, and reference intervals were analyzed following the CLSI guidelines. For precision analysis, pooled plasma and control materials were used (Bio-Rad Liquicheck Cardiac marker, Bio-Rad Laboratories, USA). 40 patients plasma were used for method comparison: hsTnI (Atellica vs Abbott Architect), NT-proBNP (Atellica vs Roche e411), myoglobin, CK-MB, BNP (Atellica vs Centaur CP). Excel 2010 (Microsoft, USA) and EP Evaluator (Data Innovations, USA) were used for statistical analyses.
Results
The observed assay repeatability ranged from 1.3 to 2.5% CV for hsTnI, 1.7 to 1.8% CV for myoglobin, 1.5 to 1.8% CV for CK-MB, 1.3 to 1.5% CV for BNP and 1.3 to 2.3% CV for NT-proBNP. Within-laboratory imprecision ranged from 2.0 to 3.6% CV for hsTnI, 1.7 to 2.6% CV for myoglobin, 2.2 to 2.3% CV for CK-MB, 2.0 to 2.3%CV for BNP and 1.8 to 2.9% CV for NT-proBNP. The tested assays showed linear regression over the whole ranges claimed by the manufacturer 
Conclusions
The novel hsTnI and other cardiac markers on Atellica IM Analyzer provide good analytical performances and shows acceptable clinical utility in patients with signs and symptoms suggestive of acute coronary syndrome. doi:10.1016/j.cca.2019.03.372
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Could lipoprotein-associated phospholipase A2 be used to predict heart failure readmission in coronary heart disease? 
Background-aim
Lipoprotein-associated phospholipase (Lp-PL) A2 is considered an anti-oxidant molecule that also exerts pro-inflammatory actions. Lp-PLA2 level is associated to the risk of coronary heart disease (CHD) and stroke. The prognosis of patients after an acute cardiovascular event is often difficult to stratify. We analyzed the association between Lp-PLA2 and short-term adverse outcomes in patients with CHD.
Methods
Prospective, observational cohort study of 108 patients with CHD, admitted to a Cardiac Care Unit from January to April of 2018. Lp-PLA2 was determined through a chemiluminescence immunoassay, according the manufacturer's instructions (Snibe Diagnostic). Patients were assigned to two groups: G1 with Lp-PLA2 b 200 ng/ml (n = 89) and G2 with Lp-PLA2 ε200ng/ml (n = 19). Cut-off was predefined, considering Lp-PLA2 ε200ng/ml portend a moderate to high risk of cardiovascular disease. Patients were followed for a period of 7-8 months.
Results
Demographic data was similar among groups, except for age (G1: 68 ± 13 vs G2: 61 ± 13 years, p = .03), LDL cholesterol (G1: 111 ± 36 vs G2: 167 ± 45 mg/dL, p = .01) and smoking habits (G1: 18% vs G2: 42% smokers, p = .02). The majority of the patients were admitted for acute coronary syndrome (40.7% for ST-Elevation MI (STEMI), 37% for non-STEMI and 12% for unstable angina), 4.6% presented with heart failure (HF), 4.6% with ventricular arrhythmias and 0.9% with pericarditis. At follow-up, there were 2 MI, 3 unscheduled revascularizations, 8 HF hospitalizations, no strokes, and 4 deaths, but none of the events was associated with Lp-PLA2. Patients with a Lp-PLA2ε 200 ng/ml had a 22-fold risk of admission due to decompensated HF, after adjusting for age, gender, LDL, smoking status, left ventricular ejection fraction and prior HF hospitalization (HR 21.9; 95%CI 1.1-231.1, p = .01).
Conclusions
Patients with CHD and Lp-PLA2 levelsε200 ng/ml were associated with a significantly increased risk of 6-month readmission due to decompensated HF. Further studies are needed to determine if Lp-PLA2 is on the causal pathway of HF or if it only reflects a higher inflammatory state that is present in severe HF. 
Background-aim
Natriuretic peptides are molecules with vasodilating and natriuretic activity, secreted by the heart to keep cardiovascular homeostasis, so they are involved in the pathophysiology of heart failure. The development of new analytical methods allows their urgent measurement, because they can play an important role in the diagnosis, management and prognosis of heart failure.
The aim is to compare the results of NT-proBNP in serum between the Cobas e601® of Roche Diagnostics and the new reagent of Siemens Healthineers for ADVIA Centaur XPT®.
Methods
Forty sera were analyzed with both assays. Statistical analysis data was performed using the non-parametric Passing-Bablock regression method and the Pearson correlation using the Analyze-it statistical package.
Results
The Passing-Bablock regression yielded a slope 1.0405 (CI 95% : 1.0087-1.0697) and intercept −2.4265 (CI 95% : -19.5366 -23.3025). The Pearson correlation between both methods is (r = 0.9958 p b .0001 CI 95% : 0.9918-0.9979).
Conclusions
Although the Pearson correlation is good, the results obtained with the Passing-Bablock test show us that the methods are not statistically interchangeable because it confirmed the absence of constant bias (intercept: CI 95% contains the value 0), but the presence of proportional bias (slope: IC 95% does not contain the value 1). Because of that, we conclude that both technologies can be used equally for diagnosis, but not for the patients follow, because it is more appropriate to monitoring it with the same methodology. 
Background-aim
Measurement of high-sensitivity troponin T (hs-TnT) has become an essential step in the diagnosis of acute myocardial infarction.
These high-sensitivity methods detect low concentrations of troponin T in blood but certain compounds in the sample may interfere with the result.
We detected a patient who had repeatedly high levels of hs-TnT that did not go hand in hand with the signs and symptoms. Therefore, we aimed to confirm and identify the interfering substance in the patient's sample.
Methods
We carried out different studies to investigate the presence of an interfering compound in the sample. Firstly, we measured the concentration of high-sensitivity troponin I (hs-TnI) in the platform Architect 2000 (Abbott Diagnostics, Chicago, Illinois, USA). We also measured the concentration of hs-TnT in Cobas e801 and e601 (Roche Diagnostics, Mannheim, Germany), both employing electrochemiluminescence immunoassays. We studied the presence of microclots, endogenous compounds (hemoglobin, bilirubin and lipemia) and the concentration of immunoglobulins A, M and G, autoantibodies and the rheumatoid factor. We also performed a dilution test, the polyethyleneglycol precipitation of the serum to discard macrocomplexes and the incubation with the Scantibodies Heterophilic Blocking Tube, which can block heterophilic antibodies. Finally, the manufacturer performed a size exclusion chromatography (SEC) to find out the molecular size that could cause interference with the hs-TnT test.
Results
The hs-TnI concentration was undetectable (b0,010 ng/mL). The concentration of hs-TnT in Cobas e801 and e601 was discordant (52 and 28 ng/mL respectively), and none of the studies performed in our laboratory guessed the cause of the interference.
The SEC analysis showed that the interference was allocated into fractions with proteins of 150 kDa, corresponding to high molecular weight proteins like immunoglobulin G (IgG).
Conclusions
The detected interfering compound is probably an IgG. Difference between hs-TnT results could be explained by the technology STAT (Short turn-around time) in the reagent of Cobas e601, which reduces the time of incubation.
This type of interference is extremely rare but it must be kept in mind in case of patients with high level of troponins without myocardial damage evidence. 
Background-aim
Lithium heparin is now widely used for the determination of biochemical parameters, including cardiac markers. However, the EDTA plasma is what recommended for the determination of BNP. If this statement is not absolute, measuring the BNP from the heparin plasma will be helpful on a STAT and integration basis. So we aimed to assess the acuity of BNP results based on heparin plasma using the ADVIA Centaur XP® kit (Siemens) .
Methods
BNP was measured in heparin plasma and EDTA plasma from 37 patients. The value of BNP performed with EDTA plasma within 30 min (H0) of blood collection was considered as the gold standard. Additional measurements were performed on the same specimens (heparin plasma and EDTA) consecutively after 1 h then 2 h of delay. These delayed plasmas were stored at room temperature (+25°c).
Results
The use of Lithium heparin was responsible for an underestimation of the BNP concentrations, compared with EDTA, by an average of 30% at H0.The concentrations of BNP were stable 2 h after blood collection in both heparin and EDTA plasmas.
Conclusions
Even performed immediately after blood collection, the measurement of BNP from Heparin plasma does not seem appropriate as compared to EDTA plasma using the ADVIA Centaur XP® system. 
Background-aim
Aging is characterized by progressive adaptation influenced by both genetic and physiological factors. There are three possible kinds of aging: normal aging, aging associated with diseases that establishment when medical conditions occur and the successful aging that contemplate three principal components: a low probability of disease, a high cognitive and physical functional capacity, and an active engagement with life. During aging cardiovascular system undergoes substantial functional and structural changes altering the levels of some cardiac function biomarkers as natriuretic peptides (PN) and endothelin-1 (ET-1) and, recently, also the adrenomedullin (ADM) system has been identified as a new biomarker associated with aging but its role in this process is not yet defined.
Aim was to evaluate the transcriptomic profile of the PN, ET-1 and ADM system in cardiac tissue of rats of different ages.
Methods
Three groups of male Wistar rats were studied: A (n = 6; age = 248 + 0.00 days-young), B (n = 13; age = 413.8 + 8.20 days-adult), C (n = 10; age = 597.6 + 10.3 days-old). Total RNA was extracted from cardiac tissue samples and analyzed by Real-Time PCR. Echocardiographic and histological evaluation completed the study.
Results
ANP and BNP mRNA levels resulted significantly higher in C (p b .01) with respect to A and B while CNP remained in a steady-state in B and C. NP receptors did not show any significant differences. ET-1 mRNA levels increased gradually and significantly as a function of age (A = 0.46 + 0.15; B = 1.50 + 0.33; C = 2.01 + 0.98; p = .013 A vs. B; p = .018 A vs. C). ET-A expression levels were statistically lower in B than A (p = .04) while ET-B were similar in all the three groups studied. The ADM showed a trend opposite to that of the other peptides studied, decreasing significantly as a function of age (A = 1.46 + 0.36; B = 0.64 + 0.17; C = 0.61 + 0.10; p = .04 A vs. B; p = .05 A vs. C) and presenting a counter-regulation of its main receptor complex CLRL and RAMP-2. Several significant correlations were observed between the analyzed genes and applying a multivariate logistic regression analysis, only LnANP (p = .003) and LnADM (p = .023) resulted significantly associated with aging. ADM trend suggests that the animals underwent to a successful aging as also confirmed by histological analysis that highlights a slight hypertrophy of cardiomyocytes and an increase in the expression of collagen fibers, a direct and non-pathological consequence of aging.
Conclusions
The study underlines the importance of a multi-label biomolecular approach in the evaluation of aging identifying, for the first time, ADM and ANP as independent aging markers and indicating the ADM as a possible predictor of successful aging. doi:10.1016/j.cca.2019.03.377
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Impact of storage conditions on the natriuretic peptides preanalytical stability using different analytical methods and biological variability concept C. Diop, P. Lukas, A. Ladang, E. Cavalier, C. Le Goff Department of Clinical Chemistry, CHU of Liege, University of Liege, Belgium
Background-aim
Studies of Brain Natriuretic Peptide (BNP) and N-terminal (NT)-proBNP pre-analytical stabilities are only expressed using statistical differences. However, having a significant statistical difference does not mean that there is a biological one. Our aim was to assess the in vitro stability of BNP and NT-proBNP at various temperatures during 48 h and using different analytical methods. We evaluated the results using approaches that consider both analytical and biological variations.
Methods
Seven EDTA tubes were obtained from 10 patients hospitalized in the intensive care unit of our hospital which agreed to participate and signed an informed consent. For each patient, one of these samples was immediately centrifuged and stored at −80°C. Then three samples were stored at room temperature (RT), the three others being stored at 4°C. After 4, 24 and 48 h, one sample was removed from each storage condition, centrifuged and stored at −80°C. All samples were thawed, centrifuged and measured in duplicate with Fujirebio Lumipulse°G BNP, Roche Elecsys proBNP II, Abbott Architect BNP and Alere NTproBNP Architect. We evaluated BNP and NT-proBNP stability using ANOVA repeated measures analysis of variance, the Acceptable Change Limit (ACL) that takes the analytical coefficient of correlation (CV) in consideration and the Total Change limit (TCL) that takes both the analytical and biological CV in consideration. Biological CV is 10% for NT-proBNP and 22.3% for BNP.
Results
Whatever method, ANOVA showed that BNP already significantly decreased after 4H at RT (p b .01). At 4°C the decrease became significant after 24H (p b .01). On the contrary, NT-proBNP remained stable up to 48H at RT.
Analytical CV was 4.0, 1.2, 1.4 and 4.1% for Abbott BNP, Roche NTproBNP, Fujirebio BNP and Abbott-Alere NT-proBNP, respectively. This derived an ACL of 11.1, 3.3, 3.9 and 11.4% for these methods, respectively. According that, BNP was stable up to 4H at RT with both techniques but at 4°C Lumipulse°G BNP showed significant degradation after 4H while Architect BNP showed none until 48H. NT-proBNP was stable at any time and temperature according to the ACL concept.
Biological and analytical CVs derived a TCL of 15.7, 6.0, 11.8 and 12.4% for Abbott BNP, Roche NT-proBNP, Fujirebio BNP and AbbottAlere NT-proBNP, respectively. This demonstrated no significant degradation of BNP until 24H at RT while it was stable up to 48H at 4°C for both techniques. NT-proBNP was also stable with the TCL concept.
Conclusions
We showed that NT-proBNP is more stable than BNP regardless of the storage conditions up to 48 h. BNP is unstable if kept at RT for N4 h but it can be kept at 4°C for 24 h without being significantly impaired. Since a result will first be important to a physician if it has a biological impact on a patient, we wanted to highlight the impact of the biological dimension. Therefore with the TCL concept, we showed that even if there is a statistical increase or decrease, samples can be kept at RT longer before showing a significant degradation, that will lead to a clinical outcome. Thus it is important to consider stabilities with tools that consider both analytical and biological variations. 
Background-aim
The Fourth Universal Definition of Myocardial Infarction recommends high-sensitivity troponin assays for routine clinical use due to their improved sensitivity and unparalleled precision at the low end. Several hospital institutions are organized by having a central laboratory and a network of smaller laboratories (hub-and-spoke). For institutions using 2 or more troponin assays, recent expert opinion recommends that differences in the sensitivity of the various assays should be tested and explained to clinicians. High-Sensitivity Troponin I (TNIH) assays performed on the Atellica IM, ADVIA Centaur, and Dimension EXL systems are immunoassays for the quantitative determination of cardiac troponin I in serum or plasma. The objective of this study was to verify the performance of the TNIH assays in a hub (Atellica® IM Analyzer and ADVIA Centaur® System) and two spoke (Dimension EXL System) laboratories.
Methods
The Atellica IM and ADVIA Centaur TNIH assays are dual-capture sandwich immunoassays using magnetic latex particles, a proprietary acridinium ester for detection, and three monoclonal antibodies. The Dimension EXL TNIH assay employs LOCI technology and three monoclonal antibodies. Precision studies were evaluated according to EP15-A3 and method comparison to EP09-A3.
Results
Precision studies were performed on QC materials close to respective 99th percentiles (within 20%). Within-Run and Total CV% were 1.7 and 2.5 at 40.3 ng/L for Atellica IM, 3.3 and 3.1 at 39.9 ng/L for ADVIA Centaur, 3.8 and 3.6 at 44.5 ng/L and 3.6 and 3.9 at 44.2 ng/L for Dimension EXL 1 and 2 systems. Method comparison for TNIH assays on ADVIA Centaur and Dimension EXL 1 and 2 systems with Atellica IM Analyzer showed regression equations as follows: y = 1.076×-1.377 (R2 = 0.997), y = 0.979×-28.642 (R2 = 0.972), y = 0.991× + 1.039 (R2 = 0.996). Overall concordance with Atellica IM TnIH Assay results on 117 samples, either above or below the 99th percentile, was 99.1% for ADVIA Centaur and 96.5% for Dimension EXL TNIH assays in both spoke sites. 
Conclusions

Background-aim
Atherosclerosis is a multifactorial complex inflammatory disease which involves different cells types including macrophages.
Macrophages comprise a heterogeneous population, including several co-existing subtypes with diverse and even opposite roles such as M1 pro-inflammatory and M2 anti-inflammatory. These cells influence the lipid metabolism, inflammatory response and plaque stability. However it has been recently recognized that the two states M1 and M2 are insufficient to describe the much broader complexity of stimuli and responses that characterizes the different subtypes of macrophages.
Methods
Metabolomics technology represents the systemic study of endogenous chemical signature of a functional metabolic phenotype and the cellular state in response to environmental factors. The aim of our study is to decipher the macrophage metabolic signature in different subtypes of macrophages; M1 pro-inflammatory macrophages, M2 anti-inflammatory macrophages, and macrophages which are exposed to high level of Glucose or Oxidized LDL which are considered as pro-atherogenic mediators for atherosclerosis.
Results
Four different methods of extraction and analysis have been developed and optimized for our investigations to determine a wide range of metabolites, using the High-performance Liquid Chromatography, Gas Chromatography Mass Spectrometry and High-performance Liquid Chromatography tandem mass spectrometry analytical techniques.
From the four employed different methods, 95 metabolites were identified. 28 metabolites exhibited high precision and their levels were compared between the different types of macrophages. Different metabolic pathways were identified as characteristic for each specific macrophages phenotype. Aerobic glycolysis is induced upon activation of M1 macrophages which increased the levels of citric acid, while M2 macrophages obtain their energy mostly from fatty acid oxidation which require increased levels of fatty acids as myristic acid and lauric acid. Fatty Acyl-CoA biosynthesis and NOS activation and regulation were shown to be characteristic of M1 phenotype. Moreover, transport of fatty acids, ABC-family protein mediators and SLC-mediated transmembrane transport were revealed as characteristic of M2 phenotype. Glutamic acid and inositol were also seen as characteristic of M2 macrophages.
Conclusions
Results from this study could help us understand the diversity of metabolic pathways involved in the regulation of macrophage activation during atherogenesis. 
Background-aim
To analyze of vascular inflammation markers in patients with unstable angina (UA) without and with type 2 diabetes (DM), to identify biochemical predictors of post revascularization unwanted events (episode of UA) after percutaneous coronary interventions (PCI).
Methods
199 patients aged 59.5 ± 6.7 years with coronary heart disease were examined. Patients UA (n = 102) without (Gr. 1, n = 79) and the presence of DM (Gr. 2, n = 23) were isolated from the general group. All patients underwent PCI with stenting. Lipid profile parameters; inflammatory markers (hs-CRP, TNF-alpha, homocysteine, interleukine 1®, 6, 8, 10; sCD40 L, MMP-9, TIMP-1); endothelial dysfunction markers (endothelin-1, nitrites) were measured. Laboratory tests were evaluated at baseline and 3, 6 and 12 months after PCI.
Results
The patients with UA and stable angina (SA) in the general group differed in the level of total cholesterol, Apo A-1, Apo B / Apo A-I, which were significantly higher in the group with SA. In the group with UA significantly higher levels of sCD40L, MMP-9 and TIMP-1 were recorded. In patients with Gr.1 a recurrent episode of post revascularization unstable angina was in 25.3% of patients, in the Gr. 2 -UA in 30%. At the same time, in e Gr.1, the dependence of repeated episode of post revascularization unstable angina on the level of IL-6 (p b .05) was found, and in the Gr.2 on the level of sCD40L, MMP-9 and TIMP-1 (p b .05). Equally elevated levels of markers of inflammation of hs-CRP, TNF-〈, endothelin-1, homocysteine in all groups support prolonged inflammatory vascular response and increase the likelihood of recurrent episodes of atherothrombosis.
Conclusions
Research on biomarkers in a period of unstable coronary conditions is very important. So, the markers sCD40L, MMP-9 and TIMP-1 can be used as differential signs of process instability at the initial stage and indicate a high risk of developing an episode of post revascularization unstable angina in patients with type 2 DM after angioplasty. 
Background-aim
Fatty acids (FA) -organic compounds belonging to the group of carboxylic acids, the molecules of which contain a different number of carbon atoms (from 10 to 20). FA are divided into saturated (only single bonds), monounsaturated (with one double bond), and polyunsaturated (with several double bonds). The Omega-3 Index reflects the relative amount of omega-3 FA within red blood cell membranes. Many studies show that a low Omega-3 Index is associated with increased risk of cardiovascular disease (CVD), and it has been proposed that raising the index may help to reduce CVD risk. Measurements of FA in red blood cell membranes can provide important information about FA intake. In different regions of the world the value of the Omega-3 Index in the population varies considerably due to the peculiarities of nutrition. The purpose of this study was to identify the effect of age and gender on the Omega-3 Index in the average Caucasian population.
Methods
Whole blood samples were obtained from 4362 people aged from 1 month to 93 years (1395 males and 2967 females). The content of FA in the blood was determined by using gas chromatography (GC) with flame ionization detector (Agilent GC-7890В). The method involves the preliminary derivatization by acetyl chloride followed by extraction with hexane. Omega-3 Index for whole blood (EPA + DHA to the total content of FA) is expressed as the percentage.
Results
It was found that the value of Omega-3 Index increases from 20 years (4.39%) to 50 years (5.38%). After 50 years the magnitude of the flex begins to decrease gradually. Depending on gender the average Omega-3 Index in men was lower than in women, respectively 4.75% versus 5.08%. The total sample by age was divided into decades. In all age groups for women the index value was higher. The highest Omega-3 Index was observed in both men and women in the period from 30 to 69 years.
Conclusions
According to the data obtained it can be concluded that the value of the Omega-3 Index corresponding to the greatest risk of CVD occurrence is observed in age periods of 20-29 years and after 70 years. The study revealed a clear dependence of the Omega-3 Index on gender and age, which requires clarification of target values for this marker of the risk of CVD. 
Background-aim
In recent years, in patients who are candidates for cardiac surgery, more attention is paid to cardiac biomarkers in terms of evaluating their predictive power. The most common criteria for evaluation of results in cardiac surgery are the rate of postoperative mortality and morbidity, the total length of hospitalization and medical costs.
The aim of this study was to test the predictive power of certain biomarkers, when predicting outcome regarding postoperative mortality, postoperative myocardial infarction and cerebrovascular complications -Major Adverse Cardiac and Cerebrovascular Events (MACCE) after cardiac surgery, in patients with low ejection fraction (EF).
Methods
The study included 704 consecutive patients with EF δ50%, who were submitted to coronary surgery, valvular surgery and combined procedures, at our Institution, in the period of two years. Following biomarkers analyses were performed 24 h prior to surgery: troponin I, creatine kinase, creatine kinase MB isoenzyme, mass creatine kinase, lactate dehydrogenase, C-reactive protein, N -terminal pro Btype natriuretic peptide and uric acid. For statistical analyses, binary logistic regression, and ROC curves were used.
Results
The MACCE were registered in 130 (18.5%) patients postoperatively. Univariate logistic regression showed relation between elevated values of troponin I (p b .0005), mass creatine kinase (p = .005), C-reactive protein (p = .004) and lactate dehydrogenase (p = .038) with MACCE, while multivariate analysis confirmed elevated preoperative value of troponin I as only predictor (p b .0005; odds ratio1.066 [1.036-1.097]).The area under the ROC curve, for troponin I was 0. 618; p b .0005.
Conclusions
The only predictor of MACCE, after cardiac surgery in patients with low left ventricular ejection fraction is elevated preoperative value of troponin I. However, it has low discriminative power and may not be good marker for MACCE prediction. 
Background-aim
Cardiovascular disease is the leading cause of morbidity and mortality in kidney transplant recipients. Several single nucleotide polymorphisms (SNPs) in the ANRIL gene pathway have been associated with cardiovascular events (CE). The main objective was to ascertain whether ANRIL (rs10757278) and CARD8 (rs2043211) SNPs could mediate susceptibility to CE.
Methods
This was an observational follow-up cohort study of renal transplant recipients at Bellvitge University Hospital (Barcelona) from 2000 to 2014. 505 recipients were followed up until achievement of a CE. CE was classified into two sub-types: ischemic stroke and myocardial event (comprising both myocardial infarction and unstable angina). A sub-study analyzing mortality as an endpoint was also developed. Mortality was classified as cardiovascular mortality and overall mortality. Patients who did not achieve the endpoint were followed up until graft loss, lost to follow-up or death. Cox regression and Kaplan Meier survival curves were used to ascertain association between genetic markers: ANRIL (rs10757278) and CARD8 (rs2043211), clinical data and outcome.
Results 53 patients (10%) suffered a CE after renal transplantation: 20 patients had an ischemic stroke and 33 patients had a myocardial event. The remaining patients (n = 452) were censored: 101 grafts were lost (44 returned to dialysis and 57 died with a functioning graft), 7 patients dropped out and 344 patients were cardiovascular event-free at the end of data collection.
Kaplan Meier survival curve for ANRIL polymorphism rs10757278 showed statistical significance in the log rank test comparing carriers of the protective allele (AA or AG) vs homozygotes for the risk allele (GG) (P = .0003). Cox regression showed a significant association between ANRIL SNP and CE. Homozygous GG for the risk allele showed higher risk for CE than A carriers for the protective allele (HR = 2.93(1.69-5.11),P b .0001). This effect was maintained when it was analyzed in combination with CARD8, suggesting that CARD8 SNP could play a role in the ANRIL mechanism. No significant association was found between ANRIL SNP rs10757278 and all-cause mortality (P = .139) nor with cardiovascular exitus (P = .761). 
Background-aim
Left ventricular assist devices (LVAD) are implanted in patients with end-stage heart failure (HF) as bridge to transplantation and are able to active neurohormonal system that entails the compensatory rise of vasocostrincting and vasodilating mediators, such as endothelin (ET) system and relaxin (RLX). RLX acts as compensatory mediator in HF and inhibits the stimulation of ET-1 probably via ET receptors enhancing ET-1 clearance and leading to improve cardiac compliance. The aim was to evaluate whether LVAD is able to modulate the RLX and ET-1 system in the heart of end-stage HF patients undergoing LVAD implant by measuring their cardiac expression.
Methods
In this study were enrolled patient candidates for LVAD implantation collected at baseline (pre-LVAD, n = 22), patients who underwent elective heart transplantation (HTx, n = 7) on medical therapy, and patients supported by LVAD as a bridge-toheart transplantation (post-LVAD, n = 6). The pre-LVAD and the HTx patients median age was comparable [58 (48-64) vs 55 (46-62) years, respectively] as well as etiology and LV ejection fraction (b25%). In post-LVAD, the median support time prior to heart transplantation was 367 days. Biopsies were collected from LV area at the time of surgical procedures and the cardiac expression of ET-1, RLX, ET-A, ET-B and ET converting enzyme (ECE)-1 was evaluated by Real-Time PCR. 
Results
RLX
Conclusions
Our results show the involvement of RLX and ET-1 axis in end stage HF patients supported by LVAD, evidencing a different regulation in LVAD group with respect to HTx. The increase of RLX expression evidenced in the post-LVAD patients might support its role as a compensatory mediator in HF also after mechanical assistance. Probably this increase, resulting in systemic vasodilatation, counterbalance the vasopressor effect of ET-1 system evidencing the effect of LVAD on phenotypic and functional changes in failing myocardium. 
Background-aim
Apelin is an endogenous peptide that binds the angiotensin-like 1 (APJ) receptor and increases cardiac contractility. The expression of apelin/APJ receptor system is differently modulated in healthy and failing heart. Although the levels of apelin pathway are increased in compensation for ischemic cardiomyopathy in animal models, its expression profile in human failing heart with similar function and different origin is still unclear. The aim of the study was to analyze the apelin/APJ mRNA profile in left ventricular (LV) tissue of patients affected by idiopathic (DCM) or ischemic (ICM) end-stage dilated cardiomyopathy undergoing cardiac transplantation.
Methods
Apelin/APJ mRNA expression was measured in LV myocardium of DCM (n = 8; age: b50 yrs.; LVEF% = 17.5 ± 3; LVEDV = 305.5 ± 110 ml) and ICM pts. (n = 8; age:b50 yrs.; LVEF% = 19.5 ± 5.2; LVEDV = 270 ± 97 ml) with similar cardiac function by Real-Time PCR analysis. All patients are affected by similar co-morbidities and received similar medications, and cardiac function was assessed by echocardiography. To understand if the difference of apelin/APJ mRNA expression depend on the origin of HF or on the magnitude of global cardiac function atrium cardiac tissue of 5 valvular disease patients (VLP), age matched, with LVEF % N50% and not pharmacologically treated were also used.
Results
Apelin mRNA expression resulted significantly higher in DCM with respect to ICM (DCM:38.7 ± 10.3; ICM:11.06 ± 6.0 p = .01) as well as APJ receptor mRNA expression (DCM:17.2 ± 3.3; ICM:11.3 ± 4.3) also if no significantly. A significant correlation was observed between Apelin and APJ receptor (r = 0.629, p = .0052). In addition, a significant increase of apelin (p = .05) and APJ receptor (p = .02) mRNA expression was observed in patients with LVEFb50% (apelin: 23.8 ± 6.08; APJ:13.8 ± 2.86) with respect to patients with LVEFN50% (apelin: 1.15 ± 0.23; APJ:1.39 ± 0.46).
Conclusions
LV apelin/APJ mRNA levels increase in patients with LVEF b50% probably due to a compensatory response to a loss of contractility. Noteworthy, LV apelin/APJ mRNA expression in DCM is higher than ICM hearts. Our results, for the first time, suggest that the induction of apelin gene expression in the failing ventricles may represent a new cardiac biomarker for an adaptative response to loss of inotropic strenght in the presence of coronary patency. 
Background-aim
The N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a widely used biomarker of cardiac dysfunction in adults, especially in the context of heart failure. Recent studies have focused on the usefulness of NT-proBNP in the field of pediatric cardiology. The cardiovascular status of the newborn infant is highly unestable, especially during fetal stressful conditions, and can affect postnatal cardiovascular function. Few studies have investigated NT-proBNP concentrations in the umbilical cord blood of neonates as a marker of fetal cardiopulmonary stress in several pathologies, comparing NTproBNP concentrations of affected neonates with healthy neonates' levels, but there are no well-established reference values.
The aim of this study is to establish reference values of umbilical cord blood NT-proBNP in healthy neonates.
Methods
Blood cord samples were collected from September 2015 to October 2016, after having obtained parental informed consent. We included 150 singleton neonates without any important pathology diagnosed up to 2 years after birth. Neonates with intrauterine growth restriction, respiratory distress or complications during pregnancy were excluded.
Umbilical cord blood was collected in tubes without additive at the time of delivery, centrifuged (3000 rpm, 5 min), supernatant was separated and frozen at −80°C until the time of the assay. Electrochemiluminescence immunoassays were performed on a Cobas 6000 (Roche Diagnostics).
Reference values were calculated following the Clinical & Laboratory Standards Institute guideline C28-A3, by the nonparametric percentile method, using the software MedCalc (v 12.5.0.0). D'Agostino-Pearson test and Tukey method were applied for normal distribution and outlier detection, respectively
Results
Median gestational age was 39 weeks (minimum = 35, maximum = 42). NT-proBNP didn't follow a normal distribution. NTproBNP median value was 553 pg/mL, ranging from 238 (90% Confidence Interval from 179 to 261) to 2280 pg/mL (90% Confidence Interval from 1538 to 2877).
Conclusions
This study provides reference values of umbilical cord blood NTproBNP, which could be applied to the routine study of neonates with suspected cardiac dysfunction, facilitating early diagnosis and management. 
Background-aim
Measuring natriuretic peptides (NP) concentrations is recommended by the European Society of Cardiology as an alternative approach for the diagnosis of both acute and chronic heart failure (HF). Standardization of current BNP and NT-proBNP assays is lacking, making results from different assays not transferable. Different antibodies, different analytical detectors and the existence of glycated, truncated forms of proBNP, BNP and NTproBNP in the bloodstream contribute to the complexity of the NP measurement. Little is known about comparability of NP results from different assays and about their thresholds-based interpretation.
Methods
This study compares EDTA plasma NT-proBNP levels from HF patients measured using 3 assays available to Hospices Civils de Lyon Laboratory and assess their agreement. NT-proBNP (Architect i2000sr®, Vista®, Cobas E601®) levels were measured in 61 samples. Only results from acute decompensated HF or new diagnosis of HF were included. 
Results
Passing
Conclusions
This study stresses the lack of transferability of NTproBNP results obtained using three different assays in fresh plasma samples. Given the differences observed between assays, HF diagnoses specific cutoffs should be determined for each commercial NP immunoassay. We recommend to systematically monitor HF patients using the same assay over the time. 
Background-aim
Biotin, also known as Vitamin B7, is a water-soluble vitamin present in some dietetic supplements (5-10 mg per day). It has also been used at high doses (300 mg per day) as a novel therapy for multiple sclerosis (MS). Recently, interferences with this substance have been reported concerning immunoassay methods based in streptavidin-biotin capture techniques. Serum biotin can compete with biotin-bound antibodies, leading to a negative interference in sandwich immunoassays.
NT-proBNP is a useful biomarker for heart failure exclusion and follow-up. To our knowledge biotin interference has not been described with the Elecsys NT-proBNP II STAT assay (Roche Diagnostics®). Despite manufacturer claims there is no interference with biotin concentration up to 30 μg/L, some patients that use biotin have serum concentrations from 30 μg/L (dietetic supplements) to above 1100 μg/L (MS therapies).
Methods
We pooled serum samples in the range of three different concentrations, and each of them was spiked with increasing dilutions of biotin solution. All samples were measured in a Roche Cobas® 6000 module 601 analyzer. Initial concentrations of NTproBNP were 428 pg/mL, 815 pg/mL, 1695 pg/mL and biotin was added through Universal Diluent at concentrations of 0 μg/L, 25 μg/L, 50 μg/L, 100 μg/L, 500 μg/L, 1000 μg/L.
In addition, we tested the neutralization protocol described by Piketty et al., using streptavidin coated microparticles (0.72 mg/mL) to capture biotin excess.
Results
A significant negative bias was observed at increasing biotin concentrations: mean absolute deviations were 1.75%, 4.84%, 9.32%, 66.04% and 96.32% for samples spiked with 25 μg/L, 50 μg/L, 100 μg/L, 500 μg/L and 1000 μg/L biotin respectively.
A mean of 93.81% was recovered after the neutralization protocol with no significant differences among assayed concentrations.
Conclusions
As biotin interference can remain unknown for clinicians, we highly recommend elaborating protocols to identify patients that can potentially be affected. Low doses of biotin can be suspended prior to sample extractions and a neutralization protocol can be used for analysis of patients treated at high doses. 
Background-aim
Guidelines recommend cardiac troponin (cTn) as the biomarker for diagnosing non-ST segment elevated myocardial infarction (NSTEMI) in chest pain (CP) patients. In big cities, CP patients can be evaluated at varied health levels, from primary care emergency centers to university hospitals. These centers measure cTn with either contemporary, including point-of-care (POC), or high-sensitive (hs-cTn) methods. Criteria for interpreting cTn values for NSTEMI diagnosis vary among guidelines. As a result, CP patients can be evaluated at different health levels that use cTn assays with different characteristics and varied criteria for interpreting cTn values.
To investigate how cTn concentrations are measured and interpreted in the different health emergency centers attending CP patients in the city of Barcelona (1.6 million people).
Methods
Cross-sectional descriptive study. Phone interview with at least a staff physician per center. Data registered were: emergency department type, attending cardiologist, cTn method, analyzer, use of an institutional protocol for MI evaluation, limit used for cTn interpretation and if it varied by gender, time interval between serial cTn measures and criteria used (delta value) to evaluate cTn rise/fall and use of additional biomarkers.
Results
All the centers (n = 20) attending CP patients in Barcelona city responded to the interview. Centers included 12 hospitals (4 university) -all them with attending cardiologists-and 8 primary care emergency centers (PCEC) attending emergencies of moderate complexity. Two PCEC centers did not measure cTn; 9 centers measured cTnT and 9 cTnI. Seven centers used hs-cTn methods and 11 (5 POC) contemporary ones. Only 2 university hospitals have an institutional protocol for MI diagnosis. All centers used a decision limit of cTn for MI diagnosis: the 99th reference percentile, the value measured with 10% imprecision or other value. Any center used differentiated cTn limits for men and women. Fifteen centers analyzed cTn serially for MI diagnosis, but only 4 used the rise/fall criteria (delta values) recommended in the literature.
Conclusions
The study shows a great heterogeneity in the measurement and criteria used for interpreting cTn values in the diagnosis of NSTEMI highlighting the need of homogenization initiatives, mostly educational, to maximize the cTn diagnostic power in all centers managing patients with suspected MI. 
Background-aim
Soluble ST2 (sST2) has been used a prognostic marker for heart failure. Previous studies indicated 35 ng/mL of sST2 as the clinical cutoff value. However, age-associated elevation of sST2 value may occur because subclinical heart disease increases with age. In this case, different decision limits may be needed for optimized therapy in elderly patients. This study aims to determine the reference intervals of sST2 in an elderly Korean population from leftover specimens.
Methods
From November to December 2018, the serum samples were collected at the Veterans hospital after completion of the routine chemistry testing including creatinine, high-sensitive troponin I (hsTnI), and B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP). Inclusion criteria were as follows: (1) patients with age 60 or older; (2) BNP b70 pg/mL for all age or NT-proBNP b75 pg/ mL for those under 75 years and b200 pg/mL for those with 75 or older; (3) hsTnI within upper reference limit (b34.2 pg/mL and 15.6 pg/mL for males and females); (4) estimated glomerular filtration rate (eGFR) N50 mL/min/1.73 m2; (5) no hemolysis; and (6) no urgent cardiovascular condition. The sST2 levels were measured using the Presage ST2 ELISA kit (Critical Diagnostics, USA). The reference range for sST2 was determined using the MedCalc Software (MedCalc Software bvba, Belgium) with nonparametric percentile method.
Results
During the study period, a total of 226 patients were included (123 males under 75 years, 80 males with 75 or older, and 23 females). The mean age (±standard deviation) of all participants was 74.3 (±7.9) years. The median sST2 concentrations were 33.8 ng/mL (interquartile range, 25.3-43.1), 32.8 ng/mL (23.7-41.6), and 35.6 ng/mL (29.6-55.6) for the entire males, those under 75 years, and those with 75 or older, respectively. sST2 levels were significantly higher in males with 75 or older than in those under 75 (P = .0023). The 97.5th percentile upper reference limits (URL) for sST2 were 85.7 ng/mL, 72.6 ng/mL, and 110.8 ng/mL for the entire males, those under 75 years, and those with 75 or older, respectively. Overall, the reference interval of total males was from 16.7 (90% confidence interval, 14.4-18.6) to 85.7 (69.8-113.9 ). For the females, although only small subjects included, the 97.5th URL was 50.5 ng/ mL.
Conclusions
Compared with the URL provided by the manufacturer (49.3 ng/ mL), that of this population revealed higher value especially in males with 75 or older showing about two-fold increase. We suggest the application of age-specific sST2 reference intervals may be considered in the elderly people. The URL value can be influenced by the proportion of old individuals. Further studies are needed including sufficiently large sample size with appropriate selection criteria. 
Background-aim
To assess the feasibility of determining the functional activity of platelets by impedance aggregation in patients (pts) with unstable angina (UA) and coronary artery stenting.
Methods
The study involved 110 pts. (mean age 61.2 ± 7.3 years) with UA and coronary artery stenting (the average number of implanted stents were 1.75 ± 0.5), the follow-up was 12 months. All pts. were evaluated coagulation-plasma hemostasis with the test of thrombin generation, determination of fibrinogen level, von Willebrand factor and flow cytometry. To assess and platelet resistance to antiplatelet agents was performed on the analyzer Multiplate (ASPI-test, ADPtest) on 5-7 day after administration of clopidogrel and acetylsalicylic acid (ASA).
Results
Initial decrease of sensitivity to clopidogrel was detected in 26 pts. (23.6%): to the original drug in 7 (6.4%) pts., to the generics -19 (17.3%) pts); decrease in sensitivity to ASA-in 21 pts. (19.1%) ; 8 pts. (7.3%) showed double resistance to clopidogrel and ASA. The decrease in sensitivity to clopidogrel was confirmed by flow cytometry data with the detection of N15% of active platelets on the background of ADP induction (28 ± 6,7%), while according to the impedance aggregometry AUC ADP -test was 72,6 ± 7,2 U, AUC ASPI -test 61,6 ± 6,8 U.
Recurrent cardiovascular complications during 12 months of follow-up developed in 31 pts. (28.2%) with UA, including 20 (18.1%) pts. with high residual platelet reactivity (HRPR) at the hospital stage of follow-up. The risk of recurrent coronary events in pts. with HRPR was significantly higher than in pts. sensitive to antiplatelets: relative risk RR = 5.5; [95% CI 2.7-19]; p = .0001. Detection of simultaneous resistance to clopidogrel and ASA was revealed in 7.3% of pts. and was associated with a high risk of recurrent coronary events during 12 months of follow-up: the RR of recurrent coronary events was 8.9 times [95% CI 6.7-31]; p = .0001 compared with pts. with good sensitivity to antiplatelets.
Conclusions: Estimation of functional activity of platelets using the impedance method of aggregatometry is reasonable for pts. with UA and stenting of the coronary arteries. The risk of recurrent coronary events in cases of HRPR is significantly higher than in pts. sensitive to antiplatelet agents.
Conclusions
Assessment of HRPR in pts. with UA and stenting and its correction may reduce the number of repeated events. 
Background-aim
One of the most studied systems about the changes during the day is the cardiovascular system. Higher blood pressure levels, elevated cortisol values, and the higher activity of coagulation factors or other systems such as renin-angiotensin-aldosterone axis, make the beginning of the active phase a period of great stress in the cardiovascular system. Chronobiology is the science that studies circadian variation in all physiological processes. The purpose of this study is to determine whether this process, that occurs in all individuals, is reflected in an orderly sequence of population data over time of values obtained from the analyte NTproBNP (amino terminal fraction of the brain B-type natriuretic propeptide).
Methods
We collected data of NT-proBNP analized in the Cobas E411 (Roche®) electrochemiluminescence immunoassay system at our hospital, between January 2014 and December 2017. We selected samples from patients aged 15 to 85 years, grouped by sex (9365 men, 6567 women). A cosinor analysis was made, calculating the mesor (or average value of the function) and acrophase (or maximum value of the function).
Results
In both groups, circadian rhythm was present (p b .05) with very similar mesor values, although slightly higher in the case of men (3792 ± 373 vs 3704 ± 460 pg/mL). The acrophases were also very similar, with a slight phase advancement in the case of men (4:11 ± 2: 45 vs 5: 02 ± 3: 53).
Conclusions
Results from this study demonstrate the presence of circadian rhythm in the population-based data in the case of NTproBNP.
Furthermore, the acrophases match in both groups at the time of higher cardiovascular stress of the day, because of the compensatory physiological function of natriuretic peptides as natural antagonists of the renin-angiotensin system and the sympathetic nervous system.
Despite the limitations of this work due to interferences with other physiological parameters not taken into account in this initial study, these findings support results from previous studies on the applicability of population data analysis to study circadian rhythms. 
Background-aim
The injury of myocardium during ischemia/reperfusion (I/R) is a complex and multifactorial process involving metabolic, morphological and contractile disorders. Klotho is a membrane-bound or soluble antiaging protein with antioxidative and antiapoptotic activity. The aim of the study was to evaluate the expression of Klotho protein in the cardiac cells during I/R.
Methods
Isolated rat hearts perfused with the Langendorff method and Human Cardiac Myocytes (HCM) were subjected to aerobic and I/R conditions. Cardiac mechanical function was expressed as the recovery of rate pressure product (RPP). Lactate dehydrogenase (LDH) activity was measured in coronary effluents as a marker of I/R injury. The expression of Klotho protein in the hearts and HCM and the secretion of Klotho into the coronary effluents was measured. To determine the protective role of Klotho, HCM were incubated in the presence of recombinant Klotho protein and the viability of cells was measured.
Results
Cardiac mechanical function (RPP) was decreased (p b .05) in hearts subjected to I/R in comparison to aerobically perfused hearts. LDH activity was significantly higher (p b .05) in I/R group. Klotho protein was expressed in rat hearts and HCM, in aerobic and I/R conditions. There was a significant increase (p b .05) in Klotho levels in coronary effluents in I/R group. Klotho levels in coronary effluents positively correlated with LDH activity (p b .05, r = 0.6) and negatively correlated with cardiac mechanical function (p b .05, r = −0,6). The concentration of Klotho in HCM was on an upward trend in I/R group. The cell surface expression of Klotho in HCM was significantly higher (p b .05) in I/R group. The treatment of HCM with recombinant Klotho resulted in increased number of live cells (p b .05) after I/R.
Conclusions
An increased expression of Klotho protein in HCM and release of Klotho protein into the extracellular space suggests a potential compensatory and cardioprotective effect. The correlation between Klotho levels and heart injury indicates that Klotho protein could be used as a marker of cardiac damage. An increased cell viability due to treatment with Klotho protein during I/R suggests the use of Klotho as a cardioprotective and therapeutic factor. 
Background-aim
An association between the acquired von Willebrand syndrome (aVWS) and aortic valve stenosis has been established in the past and the valve replacement shown to lead to factor recovery. Severe forms of aVWS are associated with loss of high-molecular-weight multimers (HMWM) due to the shear stress produced by the blood turbulence in the stenotic valve. No association has ever been demonstrated between aVWS and mitral regurgitation. The aim of this study is to investigate a possible connection between severe mitral insufficiency and von Willebrand factor and whether shear stress due to the valve regurgitation decreases after transcatheter mitral valve repair.
Methods
We enrolled 28 patients with severe mitral regurgitation and high surgical risk admitted for elective transcatheter mitral valve repair with Mitraclip system. All patients were successfully treated by TAVI, using only transfemoral/transeptal approach. In every patients we evaluated von Willebrand factor (VWF) antigen (VWF:ag), VWF activity with ristocetin cofactor (VWF:Rco), coagulation factor VIII (FVIII), ADAMTS13 and VWF multimer analysis. Blood samples were collected at time 0 (T0) before the treatment and 24 h (T1) and 48 h (T2) after valve repair.
Results
Vwf:ag value was significantly increased compared to baseline at T1 (p b .0064) and T2 (p b .0032). Also VWF:rco value was significantly increased compared to baseline at T1 (p b .0024) and T2 was significantly (p b .0004). No difference was demonstrated in ADAMTS13. Western Blot analysis showed a reduction of HMWM at baseline and confirmed the increase of HMWM expression after mitral valve repair.
Conclusions
This study for the first time shows that, similar to aortic valve, severe mitral insufficiency produces a stress shear that reduces the von Willebrand factor. Acquired von Willebrand syndrome due to mitral valve regurgitation can successfully be corrected by mitral valve repair with Mitraclip system without implanting a valve prosthesis. The molecular analysis of von Willebrand multimers showed that after Mitraclip HMWM increase, reducing the risk of bleeding. 
Background-aim
Measurement of lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) can be used as an adjunct to traditional cardiovascular risk factors for identifying individuals at higher risk of cardiovascular events. This can be performed by quantification of the protein concentration using an ELISA platform or by measuring Lp-PLA 2 activity using platelet-activating factor (PAF) analog as substrate. An enzymatic Lp-PLA 2 activity assay method using 1-O-Hexadecyl-2-acetyl-rac-glycero-3-phosphocholine (rac C16 PAF) was developed.
Methods
The newly revealed substrate specificity of lysoplasmalogenspecific phospholipase D (lysophospholipase D (LysoPLD)) was exploited. Lp-PLA 2 hydrolyzes 1-O-Hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (C16 PAF) to 1-O-Hexadecyl-2-hydroxy-sn-glycero-3-phosphocholine (LysoPAF). LysoPLD acted on LysoPAF, and the hydrolytically released choline was detected by choline oxidase.
Results
Regression analysis of Lp-PLA 2 activity measured by the enzymatic Lp-PLA 2 activity assay vs. two chemical Lp-PLA 2 activity assays, i.e. Lp-PLA 2 FS and PLAC test, and ELISA, gave the following correlation coefficients: 0.990, 0.893 and 0.785, respectively (n = 30).
Conclusions
Advantages of this enzymatic Lp-PLA 2 activity assay compared with chemical Lp-PLA 2 methods include the following; (i) only requires two reagents enabling a simple two-point linear calibration method with one calibrator (ii) no need for inhibitors of esterase-like activity in serum.
doi:10.1016/j.cca.2019.03.396
T211
What could be useful to know before using absolute highsensitive troponin delta around the 99th percentile upper reference limit? 
Background-aim
Measurement of troponins is mandatory in all patients with suspected NSTE-MI. High sensitive troponin (hs-Tn) assays have been recently recommended in preference to less sensitive ones. Rule-in and rule-out algorithms (1−3h) were suggested in order to support clinicians in interpreting the hs-Tn results alongside the clinical context. However, previous studies give warning to possible quantitative analytical shifts at these low concentration ranges that may exceed some of the deltas reported in clinical studies. Moreover, due to the fact that troponin should be trend-evaluated, each patient should have more than one sample tested in order to evaluate the absolute delta. In a laboratory equipped with more than one instrument, these samples may randomly be assayed by different instruments. This may lead to possible misclassification, as previously demonstrated with a contemporary assay. The aim of this study was to measure inter-identical-instrument bias of hs-TnI assay in our reality in order to understand if it can compromise the interpretation of absolute delta value for rapid algorithm 0-1/3 h.
Methods
One hundred fifty nine lithium/heparin anonimous plasma samples were processed (Access hsTnI, Beckman Coulter, Brea, CA, USA assay) sequentially on three DxI800 (DxI1, DxI2, DxI3). The results given by the three instruments were analyzed as followed: DxI1 versus DxI2, DxI1 versus DxI3, DxI2 versus DxI3. Statistical analysis was done using the Passing-Bablok regression, BlandAltman test, and Cohen's Kappa statistic.
Results
Passing Bablok regression did not show any significant deviation from linearity and no proportional nor constant differences were observed among instruments. Moreover, the mean absolute bias, even though among the three instruments the lowest 95%CI lower limit was −3.75 and the highest 95%CI upper limit was 3.92 ng/L, was within the acceptance limits (all results b reference change value RCV). The concordance between each couple of instruments was mostly strong.
Conclusions
Our data suggest that inter-identical-instrument bias needs to be considered before evaluating the clinical diagnostic accuracy of one absolute delta with respect to another, in order to define the minimum absolute delta that the laboratory can guarantee to the clinicians. Nevertheless, even if the laboratory has only one instrument, measurement uncertainty and RCV should be considered in interpreting values around cutoff and absolute delta respectively. 
Background-aim
A regular intake of red grape juice has cardioprotective properties, but its role on the modulation of natriuretic peptides (NPs), in particular of C-type NP (CNP), has not yet been proven. The aims were to evaluate: 1) in vivo the effects of long-term intake of Tuscany Sangiovese grape juice (SGJ) on the NPs system in a mouse model of MI; 2) in vitro the response to SGJ small RNAs of murine MCEC-1 under physiological and ischemic condition; 3) the activation of the CNP/NPR-B/NPR-C in healthy human subjects after 7 days' SGJ regular intake.
Methods 1) C57BL/6J mice (n = 33) were randomly subdivided into: Sham (n = 7), MI (n = 15) and MI fed for 4 weeks with a normal chow supplemented with Tuscany SGJ (25% vol/vol, 200 μl/die) (MI + SGJ, n = 11). Echocardiography and histological analyses were performed. Myocardial NPs transcriptional profile was investigated by Real-Time PCR. 2) MCEC-1 were treated for 24 h with a pool of SGJ small RNAs and cell viability under 24 h exposure to H2O2 was evaluated by MTT assay. 3) Human blood samples were collected from 7 subjects before and after the 7 days' intake of Tuscany SGJ. Real-time PCR reactions were performed. Total RNA and miRNAs were extracted with dedicated assays. Real-time PCR reactions were performed.
Results 1) the regular intake of SGJ significantly attenuated the infarct scar size by 32% and the post-MI increase in ANP mRNA cardiac levels, but not the post-MI increase in BNP mRNA cardiac levels. Interestingly, CNP mRNA cardiac levels were significantly increased in MI + SGJ mice compared to sham (p = .007) and MI (p = .03) groups. In MI + SGJ hearts, the mRNA expression of NP receptors (NPR) -B and -C was significantly lower than MI, whereas NPR-A gene expression was higher than MI hearts; 2) The treatment of MCEC-1 cells with Sangiovese small RNAs increased tolerance to H2O2-induced cell death (p b .0001). Moreover, the profile of grapevine miRNAs was characterized; 3) In human blood samples the activation of CNP/NPR-B/NPR-C pathway was activated after SGJ supplementation and circulating levels of plant miRNAs were significantly increased.
Conclusions
The regular intake of SGJ exerts anti-remodeling effects in a murine model of MI by inducing CNP/NPR-B/NPR-C pathway. In vitro, SGJ-derived miRNAs improve endothelial cell viability under stress. Finally, the CNP/NPR-B/NPR-C pathway activation is detectable in human subjects with higher circulating levels of grapevine miRNAs after SGJ intake. Our data may support the development of a novel nutraceutical approach for cardioprotection. 
Background-aim
Human Immunodeficiency Virus (HIV) continues as a major public health problem both in developing as well as developed nations. With the introduction of highly active antiretroviral therapy (HAART), a decline in morbidity and mortality from HIV has been observed. However, there is some evidence that HAART increases the risk of cardiovascular diseases (CVD) in people living with HIV. Thus, the study aimed at assessing the levels of serum biomarkers for risk of CVD across different HAART durations among HIV-positive individuals.
Methods
This was a descriptive cross-sectional study conducted at the Homa-Bay County Referral Hospital, Kenya. Study population consisted of male and female HIV-positive individuals on HAART between 18 and 45 years of age. Participants were enrolled into the study after consenting and meeting the recruitment criteria. 120 individuals participated in the study and provided the blood sample, which was used in the biochemical analysis. We analyzed our data using descriptive statistics.
Results
The majority of the participants (67.5%) had been on HAART for more than sixty months. Most of the study participants had total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), highdensity lipoprotein (HDL-C), glycated hemoglobin A1c (HbA1c), lipoprotein-associated phospholipase A2 (Lp-PLA2) and myeloperoxidase (MPO) levels within the reference interval (b 5.18 mmol/L, b 3.37 mmol/L, N 1.0 mmol/L, 21.2 ng/mL -167, and 21.4-229 ng/mL respectively). The proportions that had deranged levels were as follows; 14.2% (TC), 5.8% (LDL-C), 2.5% (HDL-C), 4.2% (HbA1c), 24.2% (Lp-PLA2) and 44.9% (MPO). Most of the participants with deranged levels of serum biomarkers for risk of CVD had been on HAART for N60 years.
Conclusions
Our findings demonstrate a high proportion of deranged levels of serum biomarkers for risk of CVD in prolonged HAART. We recommend conducting prospective association studies in this population to assess the linkage between high proportions of the levels of these biomarkers to long durations of HAART. 
Background-aim
Coronary revascularization is a standard therapeutic approach to ischemia, although restoration of blood flow to ischemic myocardium may result in ischemia/reperfusion (I/R) injury. The molecular basis for myocardial I/R injury is not fully understood, however it is known that degradation of contractile proteins by matrix metalloproteinases (MMPs) contributes to this process. Recent studies also showed that the excessive formation of nitric oxide (NO) and peroxynitrite (ONOO-) during oxidative stress activates MMP-2, and L-arginine/NO/asymmetric dimethylarginine (ADMA) pathway plays an important role in cardiovascular disorders including I/R injury.
The aim of the current research was to study the effects of barbiturate-based matrix metalloproteinase inhibitor on hearts subjected to I/R injury.
Methods
Human cardiac myocytes and Wistar rats hearts perfused with Langendorff method were subjected to I/R in the presence or absence of tested inhibitor. Hemodynamic parameters of heart function, cardiomyocyte contractility, LDH, MMP-2 expression and activity, inducible NOS (iNOS), ADMA, NO (nitrite/nitrate content), and myosin light chain 1 (MLC1) were measured.
Results
Treatment of hearts with 10 μM MMP-2 inhibitor resulted in complete recovery of mechanical function (39.4 vs 109.5%, p = .002), improved coronary flow (2.7 vs 11.9, p b .001) and heart rate (85.2 vs 255.3, p = .002). Data showed decreased tissue injury (p = .01) due to reduced expression and activity of MMP-2 (r = −0.70, p = .022). Reduced degradation of MLC1 (p = .001) contributed to an improved myocyte contractility (p = .001). An infusion of inhibitor into I/R hearts decreased an expression of iNOS and reduced level of ADMA (r = 0.72, p = .004), due to exogenous source of NO.
Conclusions
This study confirmed dual cardioprotective role of barbituratebased matrix metalloproteinase inhibitor during oxidative stress. Data showed that tested inhibitor suppressed MMP-2-based degradation of MLC1, hence limiting I/R injury. Moreover, as exogenous NO donor suppressed iNOS/NO/ADMA pathway, and subsequently decreased NOS uncoupling. Data support the hypothesis that tested substance may have important implications for prevention/treatment of heart I/R injury.
The study was supported by National Science Centre, grant no: 
Background-aim
Cardiac troponin I (cTnI) is currently the most reliable marker for acute myocardial infarction (AMI). Since cTnI is highly prone to proteolytic degradation, high sensitivity cTnI assays are strongly influenced by the epitope specificities of the antibodies used in these assays. Generating antibodies against certain epitopes can be very challenging with immunization and hydridoma technologies but the use of recombinant antibody libraries and suitable display and selection methods allow for a more controllable approach. We used phage display technology to develop antibodies against a highly stable epitope of cTnI located close to its N-terminal region.
Methods
A synthetic single-chain variable fragment (scFv) library provided an initial diversity of N10^10 antibody sequences. To guide the selection to a single epitope we used a combination of a full cTnI molecule and a synthetic peptide corresponding to the target epitope, as the target antigens, in an alternating order between 3 and 4 selection rounds. Identification of antibodies with the desired specificity was done by screening individual scFv clones for binding to both antigen forms. Further characterization was done by immunoassay with the scFvs expressed as alkaline phosphatase fusions.
Results
The highest frequency (2.3%) of antibodies with the desired specificity was found following a unique selection pathway in which the scFv library was first panned against the full cTnI molecule in a denatured state, then twice against the synthetic peptide and finally once more against full cTnI in its native form. Sequencing of the complementarity determining regions (CDRs) of 18 leads revealed seven unique clones. Four clones showed minimal cross-reactivity with the skeletal form of troponin I (skTnI) and a preliminary immunoassay indicated that the highest affinity clones were able to detect cTnI in the 10 ng/ml range.
Conclusions
The described antibody selection strategy offers a versatile option for the guided selection of antibodies against specific epitopes of cTnI. The strategy could also be applied to different analyte molecules with epitopes for which antibodies are difficult to obtain using more traditional technologies like immunization and hybridoma screening. 
Background-aim
Entresto™ is a first-in-class ARNi (angiotensin receptor neprilysin inhibitor) drug for heart failure (HF) therapy. It comprises angiotensin receptor blocker valsartan and neprilysin (NEP) inhibitor sacubitril. One of the important NEP substrates is an active form of B-type natriuretic peptide (BNP); augmentation of active BNP level due to NEP inhibition is considered as a possible mechanism of cardiac function improvement by ARNi. We hypothesized that products of BNP proteolysis by NEP are present in the circulation and their level might reflect NEP impact on active BNP metabolism. We suggest BNP cleavage by NEP at 17-18 aar results in BNP ring structure opening and formation of neo17-epitope (BNP-neo17 form). The aim of this study was to explore NEP-dependent BNPneo17 generation in vitro and in vivo.
Methods
We developed a BNP-neo17 specific sandwich immunoassay based on polyclonal rabbit capture antibody PAb-neo17, specific to neo17 epitope, and anti-BNP mAb 50E1 (HyTest Ltd., epitope 26-32 aar). We incubated human BNP with human and rat NEP and analyzed BNP-neo17 formation. Human BNP was injected in rats (43.7 μg/kg), with or without sacubitril treatment prior to the injection and BNP-neo17 and total BNP (by SES-BNP™ immunoassay, epitope 11-17 aar) were measured in plasma samples at different time points.
Results
We showed BNP-neo17 was formed from human BNP by human and rat NEP in vitro. BNP-neo17 was generated in rat circulation; its formation was effectively inhibited by sacubitril, while NEP inhibition had no considerable impact on total BNP level. Maximum BNPneo17 level was 0.26 and 1.68 μg/L at 8 and 4 min post-injection with and without NEP inhibition correspondingly. At 2 min we observed the maximum difference of 13.2-fold with and without sacubitril treatment.
Conclusions
For the first time, we have shown BNP-neo17 is generated in vitro and in vivo and its formation is NEP-dependent. Given this, we suggest BNP-neo17 concentration might reflect NEP contribution to circulating active BNP metabolism and serve as potential cardiac biomarker. 
Background-aim
The risk of complications in patients with ST-segment elevation myocardial infarction (STEMI) is heterogenous. Biomarkers could improve risk stratification.
Analyze whether single or combined (multimarkers) measure of 4 biomarkers: C-terminal fragment of insulin-like growth factor-4 binding protein (CT-IGFBP4), high-sensitive cardiac troponin T (hscTnT), N-terminal-proBNP (NT-proBNP) and growth differentiation factor-15 (GDF-15) could improve the risk stratification of STEMI patients.
Methods
The study included 253 STEMI patients (26.1% women; mean age 66 years) followed up for 2 years. Blood samples were obtained during the percutaneous coronary interventions. CT-IGFBP4 was measured with an enzymoimmunoassay (Mercodia) and hs-cTnT, NT-proBNP and GDF-15 with electrochemiluminometric methods (Roche Diagnostics). We analyzed discrimination capacity (area under curve ROC, AUC) and survival prediction of the single measurements and calibration and reclassification of the multimarkers strategy when added to a predictive clinical model found by multivariate analysis. End-points were in-hospital mortality, cardiovascular and all-cause mortality in the follow-up.
Results
Most of the STEMIs were severe: 25.7% were class Killip IV. During hospitalization, 33 patients (13.0%) died and 22 (8.7%) during follow-up. Biomarkers showed variable prognostic capacity to predict the end-points (AUCs from 0,611 [CT-IGFBP-4] up to 0,874 ). GDF-15 (for all events) and NT-proBNP (for cardiovascular death) showed same predictive power than the multimarkers. When added to the clinical model -including age, Killip class, estimated glomerular filtration and heart rate-GDF-15 significantly improved the discrimination, calibration and reclassification of the clinical model for all end-points whereas NT-proBNP only improved cardiovascular mortality assesment. Biomarkers could not improve the performance of the clinical model for all-cause mortality.
Conclusions
Single measures of GDF-15 and NT-proBNP showed prognostic value of severe complications and improved the performance of a well-established clinical model. Since in-hospital death was the most frequent complication of STEMI patients of the study, this finding may be of practical interest. GDF-15 should be considered as a shortterm risk biomarker in STEMI patients. 
Background-aim
NT-proBNP is an important biomarker in heart failure. Timely and accurate diagnosis of heart failure is essential for efficient medical treatment of the disease. Choosing the most optimal antibody pair for each particular platform is critical in the development of the highest-performing diagnostic tests.
Methods
We have developed seven mouse monoclonal antibodies (mAb) against human NT-proBNP. The pairing properties of these antibodies, designated as Anti-h NT-proBNP 1306 , 1307 , 1308 , 1309 , 1310 , 1311 , or 1312 , were studied on three different immunoassay platforms: europium-based fluorescence assay (FIA), acridinium ester -based chemiluminescence assay (CLIA), and lateral flow using colloidal gold particles (LF).
Selected antibody pairs were also used to measure NT-proBNP levels in 18 serum samples with varying NT-proBNP levels.
Results
The best performing antibody pairs for NT-proBNP detection consisted of mAbs with clearly distant epitopes on the antigen structure. In terms of the most sensitive pairs, both FIA and CLIA platforms yielded very similar results, with the linear detection range extending down to b100 ng/L with the most sensitive antibody pairs. However, these results did not fully correlate with the LF platform results. Certain antibody pairs, which performed very well in both FIA and CLIA, were clearly less applicable to LF as compared to other high-sensitivity mAb pairs.
Results obtained with clinical samples verified that the best antibody pairs can be used to detect NT-proBNP in serum.
Conclusions
These results demonstrate that the choice of antibodies for an NTproBNP immunoassay has a significant effect on the detection results, and that the best pairs can vary between different platforms. Pair recommendations drawn from results obtained on a certain platform can not be directly applied to other platforms that use different flow kinetics. 
Background-aim
Matrix metalloproteinase 2 (MMP-2) mediated degradation of myosin light chain 1 (MLC1) and troponin I (TnI) contributes to myocardial ischemia/reperfusion (I/R) injury. An increased activity of myosin light chain kinase (MLCK) and nitric oxide synthase (NOS) due to oxidative stress induced by I/R, leads to post-translational modifications of MLC1 and hence an increased degradation of these proteins.
We reported previously, that inhibition of both MLCK and MMP-2 protects heart against I/R injury. The aim of the current study was to explore if the addition of NOS inhibitor (1400 W) at subprotective concentration to the mixture of subprotective concentrations of MLCK and MMP-2 inhibitors (ML-7 and doxycycline (Doxy), respectively) increase a synergistic protection and led to complete protection of mechanical function of heart after I/R.
Methods
Hearts extracted from anesthetized male Wistar rats (300-350 g) were perfused in using the Langendorff model. After 25 min of stabilization, hearts were subjected to global, no-flow ischemia (20 min) in the presence or absence of inhibitors mixture and followed by 30 min of reperfusion. Next to hemodynamic parameters (coronary flow, heart rate, left ventricular developed pressure) biochemical markers of I/R injury were measured.
Results
Addition of subprotective concentration of 1400 W (1 μM) to the previously used mixture of Doxy (1 μM) and ML-7 (0.5 μM) leads to full recovery of heart contractility in comparison to each inhibitor alone or in combination (Doxy + ML-7). Improved heart contractility is associated with reduced degradation of TnI and MLC1. Reduced affinity of these proteins to MMP-2 degradation resulted from decreased expression and synthesis of iNOS/eNOS and hence decreased nitration/nitrosylation of structural proteins.
Conclusions
By addition of NOS inhibitor at subthreshold concentration into mixture of Doxy and ML-7, the synergistic effect of these drugs was improved and complete protection of mechanical function of the heart after I/R was achieved. Our data suggest that the use of combined administration of NOS, MMP-2 and MLCK inhibitors provides a novel strategy in the prevention of the heart from I/R injury and represent a safer alternative to monotherapy. 
Background-aim
In 2017 the SIPMeL Working Group on Myocardial Markers carried on a survey to verify the characteristics on the use of highsensitivity cardiac troponin (hs-cTn) assays in Italy.
Methods
122 Laboratories answered to a 63-items-Questionnaire available from 15 of May to 15 of December on the website of the Scientific Society (http://www.sipmel.it/it/comunicazione/notizie/109706). The items dedicated to hs-cTn explored its diffusion, preanalytical and analytical phases, criteria for set decision limits, control of performance and laboratory-clinical interface.
Results
73% of surveyed Laboratories use hs-cTn (43.9% hs-I, 29.3% hs-T). 61.5% introduced hs-cTn in the last 5 years. In all cases the introduction of hs-cTn induced a new relationship with the clinicians, but only 55% of respondents defined a protocol of use and one third shortened their rule in/out time. Among those using hs-cTn, 95% set the decision limit for myocardial injury to the 99°percentile, but few structures (22%) differentiated it by variables (age and sex). Only 36.5% introduced algorithms with delta values (58% a delta %). 90% of reports applied correctly measurement units. 100% of respondents performed internal quality control (IQC) and 90% external quality assessment (EQA). The introduction of hs-cTn had a positive impact on the intra-laboratory Turnaround Time (TAT) but not on the total TAT.
Conclusions
The data collected represent the current state of hs-cTn in Italy. The comparison with the literature indicates that it is necessary a continue work on adapting to guidelines in the clinical practice. The main problem is the insufficient communication between laboratory and clinic, which constitutes a major limit to the potential improvements that the introduction of hs-cTn could bring to both patients and Health Organization. 
Background-aim
European Society of Cardiology recommends a validated 0 h/1 h high-sensitivity cardiac troponin T (hscTnT) algorithm for evaluation of patients with suspected non-ST-elevation myocardial infarction (NSTEMI). The algorithm assigns patients to one of three categories: 'rule in' (treat), 'rule out' (discharge) or 'observe'. 'Rule in' category consists of patients with baseline hscTnT concentration of at least 52 ng/L OR a difference of at least 5 ng/L after 1 h. Patients are assigned to 'rule out' category with baseline hscTnT beneath 12 ng/L AND maximal difference of 3 ng/L after 1 h. The 'observe' group comprises all remaining patients. We evaluated analytical applicability of the algorithm in a multimodular setting which is suitable for higher throughput and efficiency but potentially requires higher vigilance over the analytical quality.
Methods
A series of 8 serum samples were prepared with theoretical hscTnT values ranging from 3 ng/L to 68 ng/L. A fraction of each sample was distributed to the 6 AZ Delta laboratory departments and each fraction was analyzed in tenfold for hscTnT on 6 different Cobas e601 modules (Roche Diagnostics, Switzerland). Coefficients of variation (CV) were calculated on each module separately to assess precision. Following bias (B) assessment, total error (TE) was calculated for every module at each concentration level as TE = B + 1,65xCV. Advanced statistics were used to calculate total CV of the analytical system comprising all e601 modules taking into account load balancing of each individual module.
Results
hscTnT CVs within one module ranged from 0,7% to 1,5% at a concentration level of 66 ng/L towards 0,0% to 8,1% at a concentration level of 7 ng/L. TEs are maximally 5,5% at 66 ng/L while TE ranges from 6,6% to 21,3% at 7 ng/L. Total CVs of the analytical system for all concentrations were lower than half the within-individual biological variation of 30,5%, with the highest CV of 8,8% for the lowest concentration of 7 ng/L. Absolute differences between modules were always lower than 3 ng/L for concentrations of b12 ng/L.
Conclusions
From an analytical point of view, these results demonstrate the feasibility of using the 0 h/1 h hscTnT algorithm in a multimodular setting. 
Background-aim
In the heart, cardiac Troponin I, cardiac Troponin T and Troponin C form a ternary complex (ITC) that is responsible for the regulation of muscle contraction. The measurements of cardiac Troponin I (cTnI) and cardiac Troponin T (cTnT) in the blood of patients are widely used for the diagnosis of acute myocardial infarction (AMI). The goal of this study was to describe troponin forms -complexed troponins, free molecules and their fragments -that appear in the blood of patients over different time periods following infarction.
Methods
Heparin plasma samples were taken from 38 AMI patients and analyzed by a gel filtration technique, sandwich immunofluorescent assays (utilizing mAbs that were specific to different epitopes and forms of troponins) and immunoprecipitation followed by SDS-PAGE and Western blotting (WB).
Results
It was shown that the heparin plasma samples of AMI patients contain a mixture of cardiac troponins: full-size ternary ITC complex; ternary ITC complex with lower molecular weight (LMW-ITC), where cTnT is truncated to an approximate 170-287 aar C-terminal fragment; binary IC complex containing partially truncated cTnI; several cTnT mid-fragments of 16-27 kDa that are not complexed with other troponins. Almost all full-size cTnT and the major part of a 29-kDa cTnT fragment are the components of ternary ITC complex. Over a period of time, the ratio of full-size ITC decreases whereas the ratios of LMW-ITC, IC-complex and small cTnT fragments increase.
Conclusions
It was shown for the first time that a new form of ITC complexlow molecular weight ITC -exists in the blood of AMI patients. At the early stage of AMI, full-size ITC and LMW-ITC are the main troponin forms. Meanwhile, over the course of the disease, the ratio of full-apo A-I, (a), B, C-II and E. Further optimization is needed for apos C-I and C-III. A linear response (r 2 = 0.997) was obtained for apo(a) up to 750 nmol/L in dilution series of a high apo(a) sample, indicating quantitation independent of apo(a) size polymorphism.
A harmonized cRMP for serum apolipoproteins A-I, (a), B, C-I, C-II, C-III and E has been developed which has potential for SItraceability. Critical evaluation of the method, including completeness of digestion and accuracy-based ring trials, is ongoing. In this era of Precision Medicine, a proof-of-concept candidate Reference Method for global standardization of apos is demonstrated using quantitative bottom-up proteomics. 
Background-aim
The Joint European Society of Cardiology/American College of Cardiology guidelines state that cardiac troponins (I/T) are the preferred biomarkers for detection of myocardial injury, risk stratification in patients diagnosed with acute coronary syndrome, and diagnosis of myocardial infarction. Because of the demand for accurate and precise measurement of low troponin levels there is an increased need for assays with improved analytical performance.
Methods
We have developed a rapid, fully automated high sensitivity assay for the measurement of cardiac Troponin I (cTnI) in human serum and plasma (heparin) for use on the VITROS® Systems. The VITROS® hs Troponin I (hsTnI) assay uses an immunometric technique in which cTnI present in the sample reacts simultaneously with streptavidin-conjugated antibody, bound by biotin-BSA on the wells, and a dual antibody-horseradish peroxidase (HRP) conjugate. The amount of HRP conjugate bound is directly proportional to the concentration of cTnI present in the sample. Time to first result is 15 min.
Results
The measuring range of the VITROS hsTnI assay is 1.50-30,000 ng/L. Limit of Blank (LoB), Limit of Detection (LoD) and Limit of Quantitation (LoQ) were established according to CLSI-EP-17-A2. On the VITROS Systems LoB range is 0.14-0.51 ng/L and LoD is 0.39-0.86 ng/L. The LoQ concentration at 20%CV is 1.23 ng/L and 10%CV is 1.99 ng/L. In a CLSI-EP05-A3 precision study, ten (4 serum, 4 heparin, 2 control) precision pools with mean cTnI concentrations ranging from 1.84 to 18,860 ng/L had within-run percent coefficient of variation (%CV) of 1.2% to 3.7% and within-laboratory %CV of 3.9% to 9.9%.
The 99th percentile Upper Reference Limits (URLs) were established using the non-parametric statistical method from serum and lithium heparin plasma of 952 healthy adults with normal HbA1c, eGFR, and NT-proBNP. The URL is 11 ng/L (overall serum & heparin), 9 ng/L (female serum & heparin), and 12 ng/L/13 ng/L (male serum/heparin respectively).
Conclusions
In conclusion, the VITROS® hs Troponin I demonstrates equivalent performance on the VITROS 3600 and ECi/ECiQ Immunodiagnostic and VITROS 5600/XT 7600 Integrated Systems, with a 10%CV at a concentration lower than the URL and the ability to measure cTnI above the LoD in N50% of a reference population.
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